LSD: Difference between revisions

Lysergic acid diethylamide (LSD)
INN: Lysergide
	2D structural formula and 3D models of LSD
Clinical data
Pronunciation	/daɪ eθəl ˈæmaɪd/, /æmɪd/, or /eɪmaɪd/)
Other names	Lyserg-säure-diäthylamid; LSD; LSD-25; Acid; Delysid
AHFS/Drugs.com	Reference
Dependence; liability	Low
Addiction; liability	None
Routes of; administration	By mouth, under the tongue, intravenous, intramuscular
Drug class	Psychedelic (serotonergic psychedelic)
ATC code	None;
Legal status
Legal status	AU: S9 (Prohibited substance); CA: Schedule III; DE: Anlage I (Authorized scientific use only); NZ: Class A; UK: Class A; US: Schedule I; UN: Psychotropic Schedule I;
Pharmacokinetic data
Bioavailability	71%
Protein binding	Unknown
Metabolism	Hepatic (CYP450)
Metabolites	2-Oxo-3-hydroxy-LSD
Onset of action	30–40 minutes
Elimination half-life	3.6 hours
Duration of action	8–12 hours
Excretion	Renal
Identifiers
	IUPAC name (6aR,9R)-N,N-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide;
CAS Number	50-37-3 ;
PubChem CID	5761;
IUPHAR/BPS	17;
DrugBank	DB04829 ;
ChemSpider	5558 ;
UNII	8NA5SWF92O;
ChEBI	CHEBI:6605 ;
ChEMBL	ChEMBL263881 ;
PDB ligand	7LD (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID1023231 ;
ECHA InfoCard	100.000.031
Chemical and physical data
Formula	C20H25N3O
Molar mass	323.440 g·mol−1
3D model (JSmol)	Interactive image;
Melting point	80 to 85 °C (176 to 185 °F)
	SMILES CCN(CC)C(=O)[C@H]1CN([C@@H]2Cc3c[nH]c4c3c(ccc4)C2=C1)C;
	InChI InChI=1S/C20H25N3O/c1-4-23(5-2)20(24)14-9-16-15-7-6-8-17-19(15)13(11-21-17)10-18(16)22(3)12-14/h6-9,11,14,18,21H,4-5,10,12H2,1-3H3/t14-,18-/m1/s1 ; Key:VAYOSLLFUXYJDT-RDTXWAMCSA-N ;
	(verify)

Browse history interactively

← Previous edit Next edit →

Content deleted Content added

VisualWikitext

Inline

Revision as of 07:21, 2 November 2017

Lysergic acid diethylamide (LSD), also known as acid, is a psychedelic drug known for its psychological effects. This may include altered awareness of the surroundings, perceptions, and feelings as well as sensations and images that seem real though they are not (pseudohallucinations).^[11] It is used mainly as a recreational drug and for spiritual reasons. LSD is typically either swallowed or held under the tongue.^[11] It is often sold on blotter paper, a sugar cube, or gelatin. It can also be injected.

LSD is not addictive.^[11]^[12] However, adverse psychiatric reactions such as anxiety, paranoia, and delusions are possible.^[7] LSD is in the ergoline family. LSD is sensitive to oxygen, ultraviolet light, and chlorine,^[13] though it may last for years if it is stored away from light and moisture at low temperature. In pure form it is odorless and clear or white in color.^[11] As little as 20–30 micrograms can produce an effect.^[14]

LSD was first made by Albert Hofmann in Switzerland in 1938 from ergotamine, a chemical from the fungus ergot. The laboratory name for the compound was the acronym for the German "Lyserg-säure-diäthylamid", followed by a sequential number: LSD-25.^[13]^[15] Hofmann discovered its psychedelic properties in 1943.^[16] LSD was introduced as a commercial medication under the trade-name Delysid for various psychiatric uses in 1947.^[17] In the 1950s, officials at the U.S. Central Intelligence Agency (CIA) thought the drug might be useful for mind control and chemical warfare and tested the drug on young servicemen and students, and others without their knowledge. The subsequent recreational use by youth culture in the Western world as part of 1960s counterculture resulted in its prohibition.^[18]

Uses

Medical

LSD currently has no approved uses in medicine.^[19]^[20]

Recreational

File:Pink Elephants on Parade Blotter LSD Dumbo.jpg

Pink elephant blotters containing LSD

LSD is commonly used as a recreational drug.^[21]

Spiritual

LSD is considered an entheogen because it can catalyze intense spiritual experiences, during which users may feel they have come into contact with a greater spiritual or cosmic order. Users sometimes report out of body experiences. In 1966, Timothy Leary established the League for Spiritual Discovery with LSD as its sacrament.^[22]^[23] Stanislav Grof has written that religious and mystical experiences observed during LSD sessions appear to be phenomenologically indistinguishable from similar descriptions in the sacred scriptures of the great religions of the world and the texts of ancient civilizations.^[24]

Effects

Physical

LSD can cause pupil dilation, reduced appetite, and wakefulness. Other physical reactions to LSD are highly variable and nonspecific, some of which may be secondary to the psychological effects of LSD. Among the reported symptoms are numbness, weakness, nausea, hypothermia or hyperthermia, elevated blood sugar, goose bumps, heart rate increase, jaw clenching, perspiration, saliva production, mucus production, hyperreflexia, and tremors.

Psychological

The most common immediate psychological effects of LSD are visual hallucinations and illusions (colloquially known as "trips"), which can vary greatly depending on how much is used and how the brain responds. Trips usually start within 20–30 minutes of taking LSD by mouth (less if snorted or taken intravenously), peak three to four hours after ingestion, and last up to 12 hours. Negative experiences, referred to as "bad trips", produce intense negative emotions, such as irrational fears and anxiety, panic attacks, paranoia, rapid mood swings, intrusive thoughts of hopelessness, wanting to harm others, and suicidal ideation. It is impossible to predict when a bad trip will occur.^[27]^[28] Good trips are stimulating and pleasurable, and typically involve feeling as if one is floating, disconnected from reality, feelings of joy or euphoria (sometimes called a "rush"), decreased inhibitions, and the belief that one has extreme mental clarity or superpowers.^[27]

Sensory

Some sensory effects may include an experience of radiant colors, objects and surfaces appearing to ripple or "breathe", colored patterns behind the closed eyelids (eidetic imagery), an altered sense of time (time seems to be stretching, repeating itself, changing speed or stopping), crawling geometric patterns overlaying walls and other objects, and morphing objects.^[29] Some users, including Albert Hofmann, report a strong metallic taste for the duration of the effects.^[30]

LSD causes an animated sensory experience of senses, emotions, memories, time, and awareness for 6 to 14 hours, depending on dosage and tolerance. Generally beginning within 30 to 90 minutes after ingestion, the user may experience anything from subtle changes in perception to overwhelming cognitive shifts. Changes in auditory and visual perception are typical.^[29]^[31] Visual effects include the illusion of movement of static surfaces ("walls breathing"), after image-like trails of moving objects ("tracers"), the appearance of moving colored geometric patterns (especially with closed eyes), an intensification of colors and brightness ("sparkling"), new textures on objects, blurred vision, and shape suggestibility. Users commonly report^{[weasel words]} that the inanimate world appears to animate in an inexplicable way; for instance, objects that are static in three dimensions can seem to be moving relative to one or more additional spatial dimensions.^[32] Many of the basic visual effects resemble the phosphenes seen after applying pressure to the eye and have also been studied under the name "form constants". The auditory effects of LSD may include echo-like distortions of sounds, changes in ability to discern concurrent auditory stimuli, and a general intensification of the experience of music. Higher doses often cause intense and fundamental distortions of sensory perception such as synaesthesia, the experience of additional spatial or temporal dimensions, and temporary dissociation.

Adverse effects

Of the 20 drugs ranked according to individual and societal harm by David Nutt, LSD was third to last, approximately 1/10th as harmful as alcohol. The most significant adverse effect was impairment of mental functioning while intoxicated.^[34]

Mental disorders

LSD may trigger panic attacks or feelings of extreme anxiety, known familiarly as a "bad trip." Review studies suggest that LSD likely plays a role in precipitating the onset of acute psychosis in previously healthy individuals with an increased likelihood in individuals who have a family history of schizophrenia.^[7]^[35] There is evidence that people with severe mental illnesses like schizophrenia have a higher likelihood of experiencing adverse effects from taking LSD.^[35]

Suggestibility

While publicly available documents indicate that the CIA and Department of Defense have discontinued research into the use of LSD as a means of mind control,^[36] research from the 1960s suggests that both mentally ill and healthy people are more suggestible while under its influence.^[37]^[38]^{[non-primary source needed]}

Flashbacks

Some individuals may experience "flashbacks" and a syndrome of long-term and occasionally distressing perceptual changes.^[39]^[40]

"Flashbacks" are a reported psychological phenomenon in which an individual experiences an episode of some of LSD's subjective effects after the drug has worn off, "persisting for months or years after hallucinogen use".^[41] Several studies have tried to determine the likelihood that a user of LSD, not suffering from known psychiatric conditions, will experience flashbacks. The larger studies include Blumenfeld's in 1971^[41]^[42]^[43]^[44]^[45] and Naditch and Fenwick's in 1977,^[46]^[47]^[48]^[49]^[50] which arrived at figures of 20%^[42] and 28%,^[46] respectively.^[39]^[51]^[52]

Hallucinogen persisting perception disorder (HPPD) describes a post-LSD exposure syndrome in which LSD-like visual changes are not temporary and brief, as they are in flashbacks, but instead are persistent, and cause clinically significant impairment or distress. The syndrome is a DSM-IV diagnosis. Several scientific journal articles have described the disorder.^[53] HPPD differs from flashbacks in that it is persistent and apparently entirely visual (although mood and anxiety disorders are sometimes diagnosed in the same individuals). A recent review suggests that HPPD (as defined in the DSM-IV) is uncommon and affects a distinctly vulnerable subpopulation of users.^[54]^[55]

Pregnancy

The mutagenic potential of LSD is unclear. Overall, the evidence seems to point to limited or no effect at commonly used doses.^[56]

Tolerance

Tolerance to LSD builds up over consistent use^[57] and cross-tolerance has been demonstrated between LSD, mescaline^[58] and psilocybin.^[59] This tolerance is probably caused by downregulation of 5-HT_2A receptors in the brain and diminishes a few days after cessation of use.

LSD is not addictive.^[5]^[12]^[60] Experimental evidence has demonstrated that LSD use does not yield positive reinforcement in either human or animal subjects.^[5]^[61]^[62]

Overdose

Reassurance in a calm, safe environment is beneficial. Agitation can be safely addressed with benzodiazepines such as lorazepam or diazepam. Neuroleptics such as haloperidol are recommended against because they may have adverse effects. LSD is rapidly absorbed, so activated charcoal and emptying of the stomach will be of little benefit, unless done within 30–60 minutes of ingesting an overdose of LSD. Sedation or physical restraint is rarely required, and excessive restraint may cause complications such as hyperthermia (over-heating) or rhabdomyolysis.^[63]

Massive doses require supportive care, which may include endotracheal intubation or respiratory support.^[63] Overdose has been recorded at 1,000 to 7,000μg per 100ml & 2.1 to 26 ng per ml in serum concentrations of the tartrate salt form. It is recommended that high blood pressure, tachycardia (rapid heart-beat), and hyperthermia, if present, are treated symptomatically, and that low blood pressure is treated initially with fluids and then with pressors if necessary. Intravenous administration of anticoagulants, vasodilators, and sympatholytics may be useful with massive doses.^[63]^[64]

Pharmacology

Pharmacodynamics

Binding affinities of LSD for various receptors. The lower the dissociation constant (K_i), the more strongly LSD binds to that receptor (i.e. with higher affinity). The horizontal line represents an approximate value for human plasma concentrations of LSD, and hence, receptor affinities that are above the line are unlikely to be involved in LSD's effect. Data averaged from data from the K_i Database

Most serotonergic psychedelics are not significantly dopaminergic, and LSD is therefore atypical in this regard. The agonism of the D₂ receptor by LSD may contribute to its psychoactive effects in humans.^[65]^[66]

LSD binds to most serotonin receptor subtypes except for the 5-HT₃ and 5-HT₄ receptors. However, most of these receptors are affected at too low affinity to be sufficiently activated by the brain concentration of approximately 10–20 nM.^[60] In humans, recreational doses of LSD can affect 5-HT_1A (K_i=1.1nM), 5-HT_2A (K_i=2.9nM), 5-HT_2B (K_i=4.9nM), 5-HT_2C (K_i=23nM), 5-HT_5A (K_i=9nM [in cloned rat tissues]), and 5-HT₆ receptors (K_i=2.3nM).^[67]^[68] 5-HT_5B receptors, which are not present in humans, also have a high affinity for LSD.^[69] The psychedelic effects of LSD are attributed to cross-activation of 5-HT_2A receptor heteromers.^[70] Many but not all 5-HT_2A agonists are psychedelics and 5-HT_2A antagonists block the psychedelic activity of LSD. LSD exhibits functional selectivity at the 5-HT_2A and 5HT_2C receptors in that it activates the signal transduction enzyme phospholipase A2 instead of activating the enzyme phospholipase C as the endogenous ligand serotonin does.^[71] Exactly how LSD produces its effects is unknown, but it is thought that it works by increasing glutamate release in the cerebral cortex^[60] and therefore excitation in this area, specifically in layers IV and V.^[72] LSD, like many other drugs of recreational use, has been shown to activate DARPP-32-related pathways.^[73] The drug enhances dopamine D₂ receptor protomer recognition and signaling of D₂–5-HT_2A receptor complexes,^[74] which may contribute to its psychotic effects.^[74]

The crystal structure of LSD bound in its active state to a serotonin receptor, specifically the 5-HT_2B receptor, has recently (2017) been elucidated for the first time.^[75]^[76]^[77] The LSD-bound 5-HT_2B receptor is regarded as an excellent model system for the 5-HT_2A receptor and the structure of the LSD-bound 5-HT_2B receptor was used in the study as a template to determine the structural features necessary for the activity of LSD at the 5-HT_2A receptor.^[75]^[76]^[77] The diethylamide moiety of LSD was found to be a key component for its activity, which is in accordance with the fact that the related lysergamide lysergic acid amide (LSA) is far less hallucinogenic in comparison.^[77] LSD was found to stay bound to both the 5-HT_2A and 5-HT_2B receptors for an exceptionally long amount of time, which may be responsible for its long duration of action in spite of its relatively short terminal half-life.^[75]^[76]^[77] The extracellular loop 2 leucine 209 residue of the 5-HT2B receptor forms a 'lid' over LSD that appears to trap it in the receptor, and this was implicated in the potency and functional selectivity of LSD and its very slow dissociation rate from the 5-HT₂ receptors.^[75]^[76]^[77]

Pharmacokinetics

The effects of LSD normally last between 6 and 12 hours depending on dosage, tolerance, body weight, and age.^[13] The Sandoz prospectus for "Delysid" warned: "intermittent disturbances of affect may occasionally persist for several days."^[15] Contrary to early reports and common belief, LSD effects do not last longer than the amount of time significant levels of the drug are present in the blood.^{[citation needed]}^{[contradictory]} Aghajanian and Bing (1964) found LSD had an elimination half-life of only 175 minutes (about 3 hours).^[67] However, using more accurate techniques, Papac and Foltz (1990) reported that 1 µg/kg oral LSD given to a single male volunteer had an apparent plasma half-life of 5.1 hours, with a peak plasma concentration of 5 ng/mL at 3 hours post-dose.^[78]

The pharmacokinetics of LSD were not properly determined until 2015, which is not surprising for a drug with the kind of low-μg potency that LSD possesses.^[9]^[6] In a sample of 16 healthy subjects, a single mid-range 200 μg oral dose of LSD was found to produce mean maximal concentrations of 4.5 ng/mL at a median of 1.5 hours (range 0.5–4 hours) post-administration.^[9]^[6] After attainment of peak levels, concentrations of LSD decreased following first-order kinetics with a terminal half-life of 3.6 hours for up to 12 hours and then with slower elimination with a terminal half-life of 8.9 hours thereafter.^[9]^[6] The effects of the dose of LSD given lasted for up to 12 hours and were closely correlated with the concentrations of LSD present in circulation over time, with no acute tolerance observed.^[9]^[6] Only 1% of the drug was eliminated in urine unchanged whereas 13% was eliminated as the major metabolite 2-oxo-3-hydroxy-LSD (O-H-LSD) within 24 hours.^[9]^[6] O-H-LSD is formed by cytochrome P450 enzymes, although the specific enzymes involved are unknown, and it does not appear to be known whether O-H-LSD is pharmacologically active or not.^[9]^[6] The oral bioavailability of LSD was crudely estimated as approximately 71% using previous data on intravenous administration of LSD.^[9]^[6] The sample was equally divided between male and female subjects and there were no significant sex differences observed in the pharmacokinetics of LSD.^[9]^[6]

Chemistry

LSD is a chiral compound with two stereocenters at the carbon atoms C-5 and C-8, so that theoretically four different optical isomers of LSD could exist. LSD, also called (+)-D-LSD, has the absolute configuration (5R,8R). The C-5 isomers of lysergamides do not exist in nature and are not formed during the synthesis from D-lysergic acid. Retrosynthetically, the C-5 stereocenter could be analysed as having the same configuration of the alpha carbon of the naturally occurring amino acid L-tryptophan, the precursor to all biosynthetic ergoline compounds.

However, LSD and iso-LSD, the two C-8 isomers, rapidly interconvert in the presence of bases, as the alpha proton is acidic and can be deprotonated and reprotonated. Non-psychoactive iso-LSD which has formed during the synthesis can be separated by chromatography and can be isomerized to LSD.

Pure salts of LSD are triboluminescent, emitting small flashes of white light when shaken in the dark.^[13] LSD is strongly fluorescent and will glow bluish-white under UV light.

Synthesis

LSD is an ergoline derivative. It is commonly synthesized by reacting diethylamine with an activated form of lysergic acid. Activating reagents include phosphoryl chloride^[79] and peptide coupling reagents.^[80] Lysergic acid is made by alkaline hydrolysis of lysergamides like ergotamine, a substance usually derived from the ergot fungus on agar plate; or, theoretically possible, but impractical and uncommon, from ergine (lysergic acid amide, LSA) extracted from morning glory seeds.^[81] Lysergic acid can also be produced synthetically, eliminating the need for ergotamines.^[82]^[83]

Dosage

A single dose of LSD may be between 40 and 500 micrograms—an amount roughly equal to one-tenth the mass of a grain of sand. Threshold effects can be felt with as little as 25 micrograms of LSD.^[14]^[84] Dosages of LSD are measured in micrograms (µg), or millionths of a gram. By comparison, dosages of most drugs, both recreational and medicinal, are measured in milligrams (mg), or thousandths of a gram. For example, an active dose of mescaline, roughly 0.2 to 0.5 g, has effects comparable to 100 µg or less of LSD.^[15]

In the mid-1960s, the most important black market LSD manufacturer (Owsley Stanley) distributed acid at a standard concentration of 270 µg,^[85] while street samples of the 1970s contained 30 to 300 µg. By the 1980s, the amount had reduced to between 100 and 125 µg, dropping more in the 1990s to the 20–80 µg range,^[86] and even more in the 2000s (decade).^[85]^[87]

Reactivity and degradation

"LSD," writes the chemist Alexander Shulgin, "is an unusually fragile molecule… As a salt, in water, cold, and free from air and light exposure, it is stable indefinitely."^[13]

LSD has two labile protons at the tertiary stereogenic C5 and C8 positions, rendering these centres prone to epimerisation. The C8 proton is more labile due to the electron-withdrawing carboxamide attachment, but removal of the chiral proton at the C5 position (which was once also an alpha proton of the parent molecule tryptophan) is assisted by the inductively withdrawing nitrogen and pi electron delocalisation with the indole ring.^{[citation needed]}

LSD also has enamine-type reactivity because of the electron-donating effects of the indole ring. Because of this, chlorine destroys LSD molecules on contact; even though chlorinated tap water contains only a slight amount of chlorine, the small quantity of compound typical to an LSD solution will likely be eliminated when dissolved in tap water.^[13] The double bond between the 8-position and the aromatic ring, being conjugated with the indole ring, is susceptible to nucleophilic attacks by water or alcohol, especially in the presence of light. LSD often converts to "lumi-LSD", which is inactive in human beings.^[13]

A controlled study was undertaken to determine the stability of LSD in pooled urine samples.^[88] The concentrations of LSD in urine samples were followed over time at various temperatures, in different types of storage containers, at various exposures to different wavelengths of light, and at varying pH values. These studies demonstrated no significant loss in LSD concentration at 25 °C for up to four weeks. After four weeks of incubation, a 30% loss in LSD concentration at 37 °C and up to a 40% at 45 °C were observed. Urine fortified with LSD and stored in amber glass or nontransparent polyethylene containers showed no change in concentration under any light conditions. Stability of LSD in transparent containers under light was dependent on the distance between the light source and the samples, the wavelength of light, exposure time, and the intensity of light. After prolonged exposure to heat in alkaline pH conditions, 10 to 15% of the parent LSD epimerized to iso-LSD. Under acidic conditions, less than 5% of the LSD was converted to iso-LSD. It was also demonstrated that trace amounts of metal ions in buffer or urine could catalyze the decomposition of LSD and that this process can be avoided by the addition of EDTA.

Detection in body fluids

LSD may be quantified in urine as part of a drug abuse testing program, in plasma or serum to confirm a diagnosis of poisoning in hospitalized victims or in whole blood to assist in a forensic investigation of a traffic or other criminal violation or a case of sudden death. Both the parent drug and its major metabolite are unstable in biofluids when exposed to light, heat or alkaline conditions and therefore specimens are protected from light, stored at the lowest possible temperature and analyzed quickly to minimize losses.^[89]

The apparent plasma half life of LSD is considered to be around 5.1 hours with peak plasma concentrations occurring 3 hours after administration.^[90]

History

"... affected by a remarkable restlessness, combined with a slight dizziness. At home I lay down and sank into a not unpleasant intoxicated-like condition, characterized by an extremely stimulated imagination. In a dreamlike state, with eyes closed (I found the daylight to be unpleasantly glaring), I perceived an uninterrupted stream of fantastic pictures, extraordinary shapes with intense, kaleidoscopic play of colors. After some two hours this condition faded away."

Albert Hofmann, on his first experience with LSD^[91]

LSD was first synthesized on November 16, 1938^[92] by Swiss chemist Albert Hofmann at the Sandoz Laboratories in Basel, Switzerland as part of a large research program searching for medically useful ergot alkaloid derivatives. LSD's psychedelic properties were discovered 5 years later when Hofmann himself accidentally ingested an unknown quantity of the chemical.^[93] The first intentional ingestion of LSD occurred on April 19, 1943,^[94] when Hofmann ingested 250 µg of LSD. He said this would be a threshold dose based on the dosages of other ergot alkaloids. Hofmann found the effects to be much stronger than he anticipated.^[95] Sandoz Laboratories introduced LSD as a psychiatric drug in 1947.^[96]

Beginning in the 1950s, the US Central Intelligence Agency began a research program code named Project MKULTRA. Experiments included administering LSD to CIA employees, military personnel, doctors, other government agents, prostitutes, mentally ill patients, and members of the general public in order to study their reactions, usually without the subjects' knowledge. The project was revealed in the US congressional Rockefeller Commission report in 1975.

In 1963, the Sandoz patents expired on LSD.^[86] Several figures, including Aldous Huxley, Timothy Leary, and Al Hubbard, began to advocate the consumption of LSD. LSD became central to the counterculture of the 1960s.^[97] In the early 1960s the use of LSD and other hallucinogens was advocated by new proponents of consciousness expansion such as Leary, Huxley, Alan Watts and Arthur Koestler,^[98]^[99] and according to L. R. Veysey they profoundly influenced the thinking of the new generation of youth.^[100]

The Grateful Dead were inextricably linked to LSD in the United States, and Grateful Dead concerts provided the primary distribution network for LSD through the mid-1990s.^[101]

On October 24, 1968, possession of LSD was made illegal in the United States.^[102] The last FDA approved study of LSD in patients ended in 1980, while a study in healthy volunteers was made in the late 1980s. Legally approved and regulated psychiatric use of LSD continued in Switzerland until 1993.^[103]

Society and culture

Counterculture, music and art

By the mid-1960s, the youth countercultures in California, particularly in San Francisco, had adopted the use of hallucinogenic drugs, with the first major underground LSD factory established by Owsley Stanley.^[104] From 1964, the Merry Pranksters, a loose group that developed around novelist Ken Kesey, sponsored the Acid Tests, a series of events primarily staged in or near San Francisco, involving the taking of LSD (supplied by Stanley), accompanied by light shows, film projection and discordant, improvised music known as the psychedelic symphony.^[105]^[106] The Pranksters helped popularize LSD use, through their road trips across America in a psychedelically-decorated converted school bus, which involved distributing the drug and meeting with major figures of the beat movement, and through publications about their activities such as Tom Wolfe's The Electric Kool-Aid Acid Test (1968).^[107] In both music and art, the influence of LSD was soon being more widely seen and heard thanks to the bands that participated in the Acid Tests and related events, including the Grateful Dead, Jefferson Airplane and Big Brother and the Holding Company, and through the inventive poster and album art of San Francisco-based artists like Rick Griffin, Victor Moscoso, Bonnie MacLean, Stanley Mouse & Alton Kelley, and Wes Wilson, meant to evoke the visual experience of an LSD trip.

In San Francisco's Haight-Ashbury neighborhood, brothers Ron and Jay Thelin opened the Psychedelic Shop in January 1966. The Thelins' store is regarded as the first ever head shop. The Thelins opened the store to promote safe use of LSD, which was then still legal in California. The Psychedelic Shop helped to further popularize LSD in the Haight and to make the neighborhood the unofficial capital of the hippie counterculture in the United States. Ron Thelin was also involved in organizing the Love Pageant rally, a protest held in Golden Gate park to protest California's newly adopted ban on LSD in October 1966. At the rally, hundreds of attendees took acid in unison. Although the Psychedelic Shop closed after barely a year-and-a-half in business, its role in popularizing LSD was considerable.^[108]

Lysergic Acid Diethylamide, by Lambert P. Lambert and the Gorgettes, from the album Abbra Cadaver, 1967.

A similar and connected nexus of LSD use in the creative arts developed around the same time in London. A key figure in this phenomenon in the UK was British academic Michael Hollingshead, who first tried LSD in America in 1961 while he was the Executive Secretary for the Institute of British-American Cultural Exchange. After being given a large quantity of pure Sandoz LSD (which was still legal at the time) and experiencing his first "trip", Hollingshead contacted Aldous Huxley, who suggested that he get in touch with Harvard academic Timothy Leary, and over the next few years, in concert with Leary and Richard Alpert, Hollingshead played a major role in their famous LSD research at Millbrook before moving to New York City, where he conducted his own LSD experiments. In 1965 Hollingshead returned to the UK and founded the World Psychedelic Center in Chelsea, London. Among the many famous people in the UK that Hollingshead is reputed to have introduced to LSD are artist and Hipgnosis founder Storm Thorgerson, and musicians Donovan, Keith Richards, Paul McCartney, John Lennon, and George Harrison. Although establishment concern about the new drug led to it being declared an illegal drug by the Home Secretary in 1966, LSD was soon being used widely in the upper echelons of the British art and music scene, including members of the Beatles, the Rolling Stones, the Moody Blues, the Small Faces, Pink Floyd, Jimi Hendrix and others, and the products of these experiences were soon being both heard and seen by the public with singles like The Small Faces' "Itchycoo Park" and LPs like the Beatles' Sgt Pepper's Lonely Hearts Club Band and Cream's Disraeli Gears, which featured music that showed the obvious influence of the musicians' recent psychedelic excursions, and which were packaged in elaborately-designed album covers that featured vividly-coloured psychedelic artwork by artists like Peter Blake, Martin Sharp, Hapshash and the Coloured Coat (Nigel Waymouth and Michael English) and art/music collective "The Fool".

In the 1960s, musicians from psychedelic music and psychedelic rock bands began to refer (at first indirectly, and later explicitly) to the drug and attempted to recreate or reflect the experience of taking LSD in their music. A number of features are often included in psychedelic music. Exotic instrumentation, with a particular fondness for the sitar and tabla are common.^[109] Electric guitars are used to create feedback, and are played through wah wah and fuzzbox effect pedals.^[110] Elaborate studio effects are often used, such as backwards tapes, panning, phasing, long delay loops, and extreme reverb.^[111] In the 1960s there was a use of primitive electronic instruments such as early synthesizers and the theremin.^[112]^[113] Later forms of electronic psychedelia also employed repetitive computer-generated beats.^[114] Songs allegedly referring to LSD include John Prine's "Illegal Smile" and The Beatles' song Lucy in the Sky with Diamonds, although the authors of the latter song repeatedly denied this claim.^[115]^[116]^[117] Psychedelic experiences were also reflected in psychedelic art, literature and film.^[118]

LSD had a strong influence on the Grateful Dead and the culture of Deadheads, as well as the impact for artist Keith Haring, early techno music, and the jam band Phish.^[101]

Legal status

The United Nations Convention on Psychotropic Substances (adopted in 1971) requires the signing parties to prohibit LSD. Hence, it is illegal in all countries that were parties to the convention, including the United States, Australia, New Zealand, and most of Europe. However, enforcement of those laws varies from country to country. Medical and scientific research with LSD in humans is permitted under the 1971 UN Convention.^[119]

Australia

LSD is a Schedule 9 prohibited substance in Australia under the Poisons Standard (February 2017).^[120] A Schedule 9 substance is a substance which may be abused or misused, the manufacture, possession, sale or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of Commonwealth and/or State or Territory Health Authorities.^[120]

In Western Australia section 9 of the Misuse of Drugs Act 1981 provides for summary trial before a magistrate for possession of less than 0.004g; section 11 provides rebuttable presumptions of intent to sell or supply if the quantity is 0.002g or more, or of possession for the purpose of trafficking if 0.01g.^[121]

Canada

In Canada, LSD is a controlled substance under Schedule III of the Controlled Drugs and Substances Act.^[122] Every person who seeks to obtain the substance, without disclosing authorization to obtain such substances 30 days before obtaining another prescription from a practitioner, is guilty of an indictable offense and liable to imprisonment for a term not exceeding 3 years. Possession for purpose of trafficking is an indictable offense punishable by imprisonment for 10 years.

United Kingdom

In the United Kingdom, LSD is a Schedule 1 Class 'A' drug. This means it has no recognized legitimate uses and possession of the drug without a license is punishable with 7 years' imprisonment and/or an unlimited fine, and trafficking is punishable with life imprisonment and an unlimited fine (see main article on drug punishments Misuse of Drugs Act 1971).

In 2000, after consultation with members of the Royal College of Psychiatrists' Faculty of Substance Misuse, the UK Police Foundation issued the Runciman Report which recommended "the transfer of LSD from Class A to Class B".^[123]

In November 2009, the UK Transform Drug Policy Foundation released in the House of Commons a guidebook to the legal regulation of drugs, After the War on Drugs: Blueprint for Regulation, which details options for regulated distribution and sale of LSD and other psychedelics.^[124]

United States

LSD is Schedule I in the United States, according to the Controlled Substances Act of 1970.^[125] This means LSD is illegal to manufacture, buy, possess, process, or distribute without a license from the Drug Enforcement Administration (DEA). By classifying LSD as a Schedule I substance, the DEA holds that LSD meets the following three criteria: it is deemed to have a high potential for abuse; it has no legitimate medical use in treatment; and there is a lack of accepted safety for its use under medical supervision. There are no documented deaths from chemical toxicity; most LSD deaths are a result of behavioral toxicity.^[126]

There can also be substantial discrepancies between the amount of chemical LSD that one possesses and the amount of possession with which one can be charged in the U.S. This is because LSD is almost always present in a medium (e.g. blotter or neutral liquid), and the amount that can be considered with respect to sentencing is the total mass of the drug and its medium. This discrepancy was the subject of 1995 United States Supreme Court case, Neal v. U.S.^[127]

Lysergic acid and lysergic acid amide, LSD precursors, are both classified in Schedule III of the Controlled Substances Act. Ergotamine tartrate, a precursor to lysergic acid, is regulated under the Chemical Diversion and Trafficking Act.

Mexico

In April 2009, the Mexican Congress approved changes in the General Health Law that decriminalized the possession of illegal drugs for immediate consumption and personal use, allowing a person to possess a moderate amount of LSD. The only restriction is that people in possession of drugs should not be within a 300-meter radius of schools, police departments, or correctional facilities. Marijuana, along with cocaine, opium, heroin, and other drugs were also decriminalized, it will not be considered as a crime as long as the dose does not exceed the limit established in the General Health Law.^[128] Many question this, as cocaine is as much synthesised as heroin, both are produced as extracts from plants. The law establishes very low amount thresholds and strictly defines personal dosage. For those arrested with more than the threshold allowed by the law this can result in heavy prison sentences, as they will be assumed to be small traffickers even if there are no other indications that the amount was meant for selling.^[129]

Czech Republic

In the Czech Republic, until 31 December 1998 only drug possession "for other person" (i.e. intent to sell) was criminal (apart from production, importation, exportation, offering or mediation, which was and remains criminal) while possession for personal use remained legal.^[130]

On 1 January 1999, an amendment of the Criminal Code, which was necessitated in order to align the Czech drug rules with the Single Convention on Narcotic Drugs, became effective, criminalizing possession of "amount larger than small" also for personal use (Art. 187a of the Criminal Code) while possession of small amounts for personal use became a misdemeanor.^[130]

The judicial practice came to the conclusion that the "amount larger than small" must be five to ten times larger (depending on drug) than a usual single dose of an average consumer.^[131]

Under the Regulation No. 467/2009 Coll, possession of more than 5 doses of LSD was to be considered smaller than large for the purposes of the Criminal Code and was to be treated as a misdemeanor subject to a fine equal to a parking ticket.^[132]

Ecuador

According to the 2008 Constitution of Ecuador, in its Article 364, the Ecuadorian state does not see drug consumption as a crime but only as a health concern.^[133] Since June 2013 the State drugs regulatory office CONSEP has published a table which establishes maximum quantities carried by persons so as to be considered in legal possession and that person as not a seller of drugs.^[133]^[134]^[135] The "CONSEP established, at their latest general meeting, that the 0.020 milligrams of LSD shal be considered the maximum consumer amount.^[136]

Economics

Production

An active dose of LSD is very minute, allowing a large number of doses to be synthesized from a comparatively small amount of raw material. Twenty five kilograms of precursor ergotamine tartrate can produce 5–6 kg of pure crystalline LSD; this corresponds to 100 million doses. Because the masses involved are so small, concealing and transporting illicit LSD is much easier than smuggling cocaine, cannabis, or other illegal drugs.^[137]

Manufacturing LSD requires laboratory equipment and experience in the field of organic chemistry. It takes two to three days to produce 30 to 100 grams of pure compound. It is believed that LSD is not usually produced in large quantities, but rather in a series of small batches. This technique minimizes the loss of precursor chemicals in case a step does not work as expected.^[137]^{[dead link]}

Forms

LSD is produced in crystalline form and then mixed with excipients or redissolved for production in ingestible forms. Liquid solution is either distributed in small vials or, more commonly, sprayed onto or soaked into a distribution medium. Historically, LSD solutions were first sold on sugar cubes, but practical considerations forced a change to tablet form. Appearing in 1968 as an orange tablet measuring about 6 mm across, "Orange Sunshine" acid was the first largely available form of LSD after its possession was made illegal. Tim Scully, a prominent chemist, made some of these tablets, but said that most "Sunshine" in the USA came by way of Ronald Stark, who imported approximately thirty-five million doses from Europe.^[138]

Over a period of time, tablet dimensions, weight, shape and concentration of LSD evolved from large (4.5–8.1 mm diameter), heavyweight (≥150 mg), round, high concentration (90–350 µg/tab) dosage units to small (2.0–3.5 mm diameter) lightweight (as low as 4.7 mg/tab), variously shaped, lower concentration (12–85 µg/tab, average range 30–40 µg/tab) dosage units. LSD tablet shapes have included cylinders, cones, stars, spacecraft, and heart shapes. The smallest tablets became known as "Microdots".^[139]

After tablets came "computer acid" or "blotter paper LSD", typically made by dipping a preprinted sheet of blotting paper into an LSD/water/alcohol solution.^[138]^[139] More than 200 types of LSD tablets have been encountered since 1969 and more than 350 blotter paper designs have been observed since 1975.^[139] About the same time as blotter paper LSD came "Windowpane" (AKA "Clearlight"), which contained LSD inside a thin gelatin square a quarter of an inch (6 mm) across.^[138] LSD has been sold under a wide variety of often short-lived and regionally restricted street names including Acid, Trips, Uncle Sid, Blotter, Lucy, Alice and doses, as well as names that reflect the designs on the sheets of blotter paper.^[140]^[141] Authorities have encountered the drug in other forms—including powder or crystal, and capsule.^[142]

Modern distribution

LSD manufacturers and traffickers in the United States can be categorized into two groups: A few large-scale producers, and an equally limited number of small, clandestine chemists, consisting of independent producers who, operating on a comparatively limited scale, can be found throughout the country.^[143] As a group, independent producers are of less concern to the Drug Enforcement Administration than the larger groups because their product reaches only local markets.^[144]

Many LSD dealers and chemists describe a religious or humanitarian purpose that motivates their illicit activity. Nicholas Schou's book Orange Sunshine: The Brotherhood of Eternal Love and Its Quest to Spread Peace, Love, and Acid to the World describes one such group, the Brotherhood of Eternal Love. The group was a major American LSD trafficking group in the late 1960s and early 1970s.^[145]

In the second half of the 20th century, dealers and chemists loosely associated with the Grateful Dead like Owsley Stanley, Nicholas Sand, Karen Horning, Sarah Maltzer, "Dealer McDope," and Leonard Pickard played an essential role in distributing LSD.^[101]

Mimics

LSD blotter acid mimic actually containing DOC

Since 2005, law enforcement in the United States and elsewhere has seized several chemicals and combinations of chemicals in blotter paper which were sold as LSD mimics, including DOB,^[146]^[147] a mixture of DOC and DOI,^[148] 25I-NBOMe,^[149] and a mixture of DOC and DOB.^[150] Street users of LSD are often under the impression that blotter paper which is actively hallucinogenic can only be LSD because that is the only chemical with low enough doses to fit on a small square of blotter paper. While it is true that LSD requires lower doses than most other hallucinogens, blotter paper is capable of absorbing a much larger amount of material. The DEA performed a chromatographic analysis of blotter paper containing 2C-C which showed that the paper contained a much greater concentration of the active chemical than typical LSD doses, although the exact quantity was not determined.^[151] Blotter LSD mimics can have relatively small dose squares; a sample of blotter paper containing DOC seized by Concord, California police had dose markings approximately 6 mm apart.^[152] Several deaths have been attributed to 25I-NBOMe.^[153]^[154]^[155]^[156]

Research

A number of organizations—including the Beckley Foundation, MAPS, Heffter Research Institute and the Albert Hofmann Foundation—exist to fund, encourage and coordinate research into the medicinal and spiritual uses of LSD and related psychedelics.^[157] New clinical LSD experiments in humans started in 2009 for the first time in 35 years.^[158] As it is illegal in many areas of the world, potential medical uses are difficult to study.^[19]

In 2001 the United States Drug Enforcement Administration stated that LSD "produces no aphrodisiac effects, does not increase creativity, has no lasting positive effect in treating alcoholics or criminals, does not produce a 'model psychosis', and does not generate immediate personality change."^[159] More recently, experimental uses of LSD have included the treatment of alcoholism^[160] and pain and cluster headache relief.^[161]

Psychedelic therapy

In the 1950s and 1960s LSD was used in psychiatry to enhance psychotherapy known as psychedelic therapy. Some psychiatrists^[who?] believed LSD was especially useful at helping patients to "unblock" repressed subconscious material through other psychotherapeutic methods,^[162] and also for treating alcoholism.^[163]^[164] One study concluded, "The root of the therapeutic value of the LSD experience is its potential for producing self-acceptance and self-surrender,"^[165] presumably by forcing the user to face issues and problems in that individual's psyche.

Two recent reviews concluded that conclusions drawn from most of these early trials are unreliable due to serious methodological flaws. These include the absence of adequate control groups, lack of followup, and vague criteria for therapeutic outcome. In many cases studies failed to convincingly demonstrate whether the drug or the therapeutic interaction was responsible for any beneficial effects.^[166]^[167]

In recent years organizations like the Multidisciplinary Association for Psychedelic Studies have renewed clinical research of LSD.^[168]

Other uses

In the 1950s and 1960s, some psychiatrists (e.g. Oscar Janiger) explored the potential effect of LSD on creativity. Experimental studies attempted to measure the effect of LSD on creative activity and aesthetic appreciation.^[169]^[170]^[171]^[172]

Since 2008 there has been ongoing research into using LSD to alleviate anxiety for terminally ill cancer patients coping with their impending deaths.^[173]^[174]

A 2012 meta-analysis found evidence that a single dose of LSD in conjunction with various alcoholism treatment programs was associated with a decrease in alcohol abuse, lasting for several months, but no effect was seen at one year. Adverse events included seizure, moderate confusion and agitation, nausea, vomiting, and acting in a bizarre fashion.^[175]

LSD has been used as a treatment for cluster headaches with positive results in some small studies.^[161]^[176]

Notable individuals

Some notable individuals have commented publicly on their experiences with LSD.^[177]^[178] Some of these comments date from the era when it was legally available in the US and Europe for non-medical uses, and others pertain to psychiatric treatment in the 1950s and 1960s. Still others describe experiences with illegal LSD, obtained for philosophic, artistic, therapeutic, spiritual, or recreational purposes.

Richard Feynman, a notable physicist at California Institute of Technology, tried LSD during his professorship at Caltech. Feynman largely sidestepped the issue when dictating his anecdotes; he mentions it in passing in the "O Americano, Outra Vez" section.^[179]^[180]
Jerry Garcia stated in a July 3, 1989 interview for Relix Magazine, in response to the question "Have your feelings about LSD changed over the years?," "They haven’t changed much. My feelings about LSD are mixed. It’s something that I both fear and that I love at the same time. I never take any psychedelic, have a psychedelic experience, without having that feeling of, “I don’t know what’s going to happen.” In that sense, it’s still fundamentally an enigma and a mystery."^[181]
Bill Gates implied in an interview with Playboy that he tried LSD during his youth.^[182]
Aldous Huxley, author of Brave New World, became a user of psychedelics after moving to Hollywood. He was at the forefront of the counterculture's experimentation with psychedelic drugs, which led to his 1954 work The Doors of Perception. Dying from cancer, he asked his wife on 22 November 1963 to inject him with 100 µg of LSD. He died later that day.^[183]
Steve Jobs, co-founder and former CEO of Apple Inc., said, "Taking LSD was a profound experience, one of the most important things in my life."^[184]
In a 2004 interview, Paul McCartney said that The Beatles' songs "Day Tripper" and "Lucy in the Sky with Diamonds" are about LSD, although John Lennon explicitly declared that "Lucy" was never about LSD but rather inspired by a picture drawn by his son Julian.^[185]^[186] John Lennon, George Harrison, and Ringo Starr also experimented with the drug, although McCartney cautioned that "it's easy to overestimate the influence of drugs on the Beatles' music."^[187]
Kary Mullis is reported to credit LSD with helping him develop DNA amplification technology, for which he received the Nobel Prize in Chemistry in 1993.^[188]

References

^ "Definition of "amide"". Collins English Dictionary. Retrieved January 31, 2015.
^ "American Heritage Dictionary Entry: amide". Ahdictionary.com. Retrieved January 31, 2015.
^ "amide - definition of amide in English from the Oxford dictionary". Oxforddictionaries.com. Retrieved January 31, 2015.
^ Halpern, John H.; Suzuki, Joji; Huertas,, Pedro E.; Passie, Torsten (June 7, 2014). Price, Lawrence H.; Stolerman, Ian P. (eds.). Encyclopedia of Psychopharmacology A Springer Live Reference. Heidelberg, Germany: Springer-Verlag Berlin Heidelberg. pp. 1–5. ISBN 978-3-642-27772-6. Retrieved April 24, 2015. Hallucinogen abuse and dependence are known complications resulting from the illicit use of drugs in this category, such as LSD and psilocybin. Users do not experience withdrawal symptoms, but the general criteria for substance abuse and dependence otherwise apply. Dependence is estimated in approximately 2 % of recent-onset users in the United States.{{cite book}}: CS1 maint: extra punctuation (link)
^ ^a ^b ^c Malenka RC, Nestler EJ, Hyman SE (2009). "Chapter 15: Reinforcement and Addictive Disorders". In Sydor A, Brown RY (eds.). Molecular Neuropharmacology: A Foundation for Clinical Neuroscience (2nd ed.). New York: McGraw-Hill Medical. p. 375. ISBN 9780071481274. Several other classes of drugs are categorized as drugs of abuse but rarely produce compulsive use. These include psychedelic agents, such as lysergic acid diethylamide (LSD), which are used for their ability to produce perceptual distortions at low and moderate doses. The use of these drugs is associated with the rapid development of tolerance and the absence of positive reinforcement (Chapter 6). Partial agonist effects at 5HT2A receptors are implicated in the psychedelic actions of LSD and related hallucinogens. 3,4-Methylenedioxymethamphetamine (MDMA), commonly called ecstasy, is an amphetamine derivative. It produces a combination of psychostimulant-like and weak LSD-like effects at low doses. Unlike LSD, MDMA is reinforcing—most likely because of its interactions with dopamine systems—and accordingly is subject to compulsive abuse. The weak psychedelic effects of MDMA appear to result from its amphetamine-like actions on the serotonin reuptake transporter, by means of which it causes transporter-dependent serotonin efflux. MDMA has been proven to produce lesions of serotonin neurons in animals and humans.
^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k ^l ^m Dolder PC, Schmid Y, Haschke M, Rentsch KM, Liechti ME (2015). "Pharmacokinetics and Concentration-Effect Relationship of Oral LSD in Humans". Int. J. Neuropsychopharmacol. 19 (1): pyv072. doi:10.1093/ijnp/pyv072. PMC 4772267. PMID 26108222.
^ ^a ^b ^c Passie T, Halpern JH, Stichtenoth DO, Emrich HM, Hintzen A (2008). "The Pharmacology of Lysergic Acid Diethylamide: a Review". CNS Neuroscience & Therapeutics. 14 (4): 295–314. doi:10.1111/j.1755-5949.2008.00059.x. PMID 19040555.
^ Neinstein, Lawrence S. (2008). Adolescent Health Care: A Practical Guide. Lippincott Williams & Wilkins. p. 931. ISBN 9780781792561.
^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j Mucke HA (2016). "From Psychiatry to Flower Power and Back Again: The Amazing Story of Lysergic Acid Diethylamide". Assay Drug Dev Technol. 14: 276–281. doi:10.1089/adt.2016.747. PMID 27392130.
^ Kranzler, Henry R.; Ciraulo, Domenic A. (April 2, 2007). Clinical Manual of Addiction Psychopharmacology. American Psychiatric Pub. p. 216. ISBN 9781585626632.
^ ^a ^b ^c ^d "What are hallucinogens?". National Institute of Drug Abuse. January 2016. Retrieved April 24, 2016.
^ ^a ^b Lüscher C, Ungless MA (November 2006). "The Mechanistic Classification of Addictive Drugs". PLoS Med. 3 (11): e437. doi:10.1371/journal.pmed.0030437. PMC 1635740. PMID 17105338.{{cite journal}}: CS1 maint: unflagged free DOI (link)
^ ^a ^b ^c ^d ^e ^f ^g Alexander and Ann Shulgin. "LSD", in TiHKAL (Berkeley: Transform Press, 1997). ISBN 0-9630096-9-9.
^ ^a ^b Greiner T, Burch NR, Edelberg R (1958). "Psychopathology and psychophysiology of minimal LSD-25 dosage; a preliminary dosage-response spectrum". AMA Arch Neurol Psychiatry. 79 (2): 208–10. doi:10.1001/archneurpsyc.1958.02340020088016. PMID 13497365.
^ ^a ^b ^c Hofmann, Albert. LSD—My Problem Child (McGraw-Hill, 1980). ISBN 0-07-029325-2.
^ "Hallucinogenic effects of LSD discovered". The History Channel.
^ Arthur Stoll and Albert Hofmann LSD Patent April 30, 1943 in Switzerland and March 23, 1948 in the United States.
^ "LSD: cultural revolution and medical advances". Royal Society of Chemistry. Retrieved September 27, 2007.
^ ^a ^b Nutt, David J.; King, Leslie A.; Nichols, David E. (August 1, 2013). "Effects of Schedule I drug laws on neuroscience research and treatment innovation". Nature Reviews Neuroscience. 14 (8): 577–585. doi:10.1038/nrn3530. ISSN 1471-003X. PMID 23756634.
^ "Scientists study possible health benefits of LSD and ecstasy | Science | The Guardian". July 23, 2016. Archived from the original on July 23, 2016. Retrieved 2016-07-23. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
^ "DrugFacts: Hallucinogens - LSD, Peyote, Psilocybin, and PCP". National Institute on Drug Abuse. December 2014. Retrieved February 17, 2015.
^ Alcohol and Drugs in North America: A Historical Encyclopedia, by David M. Fahey and Jon S. Miller, Editors, ISBN 978-1-59884-478-8, page 375
^ San Francisco Chronicle September 20, 1966 Page One
^ Grof, Stanislav; Joan Halifax Grof (1979). Realms of the Human Unconscious (Observations from LSD Research). London: Souvenir Press (E & A) Ltd. pp. 13–14. ISBN 0-285-64882-9.
^ NIDA InfoFacts: Hallucinogens - LSD, Peyote, Psilocybin, and PCP The National Institute on Drug Abuse (NIDA). Revised 06/09
^ Schiff PL (2006). "Ergot and its alkaloids". American Journal of Pharmaceutical Education. 70 (5): 98. doi:10.5688/aj700598. PMC 1637017. PMID 17149427.
^ ^a ^b Rogge, Timothy (May 21, 2014), Substance use - LSD, MedlinePlus, U.S. National Library of Medicine, retrieved July 14, 2016
^ CESAR (October 29, 2013), LSD, Center for Substance Abuse Research, University of Maryland, archived from the original on July 15, 2016, retrieved July 14, 2016 {{citation}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
^ ^a ^b Linton Harriet B.; Langs Robert J. (1962). "Subjective Reactions to Lysergic Acid Diethylamide (LSD-25)" (PDF). Arch. Gen. Psychiatry. 6 (5): 352–68. doi:10.1001/archpsyc.1962.01710230020003.
^ Albert Hofmann. "5. From Remedy to Inebriant". LSD: My Problem Child. ...taste of metal on the palate.
^ Katz MM, Waskow IE, Olsson J (1968). "Characterizing the psychological state produced by LSD" (PDF). J Abnorm Psychol. 73 (1): 1–14. doi:10.1037/h0020114. PMID 5639999.
^ See, e.g., Gerald Oster's article "Moiré patterns and visual hallucinations". Psychedelic Rev. No. 7 (1966): 33–40.
^ Nutt, D; King, LA; Saulsbury, W; Blakemore, C (March 24, 2007). "Development of a rational scale to assess the harm of drugs of potential misuse". Lancet. 369 (9566): 1047–53. doi:10.1016/s0140-6736(07)60464-4. PMID 17382831.
^ Nutt, David J.; King, Leslie A.; Phillips, Lawrence D. (November 6, 2010). "Drug harms in the UK: a multicriteria decision analysis". Lancet. 376 (9752): 1558–1565. doi:10.1016/S0140-6736(10)61462-6. ISSN 1474-547X. PMID 21036393.
^ ^a ^b Murray RM, Paparelli A, Morrison PD, Marconi A, Di Forti M (October 2013), "What can we learn about schizophrenia from studying the human model, drug-induced psychosis?", American Journal of Medical Genetics Part B, 162 (7, Special Issue: Identifying the Origins of Mental Illness: A Festschrift in Honor of Ming T. Tsuang): 661–670, doi:10.1002/ajmg.b.32177
^ "Is Military Research Hazardous to Veterans Health? Lessons Spanning Half A Century, part F. HALLUCINOGENS". December 8, 1994 John D. Rockefeller IV, West Virginia: 103rd Congress, 2nd Session-S. Prt. 103-97; Staff Report prepared for the committee on veterans' affairs. December 8, 1994.{{cite web}}: CS1 maint: location (link)
^ Middlefell R (March 1967). "The effects of LSD on body sway suggestibility in a group of hospital patients" (PDF). Br J Psychiatry. 113 (496): 277–80. doi:10.1192/bjp.113.496.277. PMID 6029626.
^ Sjoberg BM, Hollister LE (November 1965). "The effects of psychotomimetic drugs on primary suggestibility". Psychopharmacologia. 8 (4): 251–62. doi:10.1007/BF00407857. PMID 5885648.
^ ^a ^b Lerner AG, Gelkopf M, Skladman I, Oyffe I, Finkel B, Sigal M, Weizman A (2002). "Flashback and Hallucinogen Persisting Perception Disorder: Clinical aspects and pharmacological treatment approach". The Israel Journal of Psychiatry and Related Sciences. 39 (2): 92–9. PMID 12227234.
^ Halpern JH, Pope HG (2003). "Hallucinogen persisting perception disorder: What do we know after 50 years?". Drug and Alcohol Dependence. 69 (2): 109–19. doi:10.1016/S0376-8716(02)00306-X. PMID 12609692.
^ ^a ^b Halpern, J (2003). "Hallucinogen persisting perception disorder: what do we know after 50 years?". Drug and Alcohol Dependence. 69 (2): 109–119. doi:10.1016/S0376-8716(02)00306-X. ISSN 0376-8716. PMID 12609692.
^ ^a ^b Blumenfield M (1971). "Flashback phenomena in basic trainees who enter the US Air Force". Military Medicine. 136 (1): 39–41. PMID 5005369.
^ Hemsley, D.R.; Ward, E.S. (1985). "Individual differences in reaction to the abuse of LSD". Personality and Individual Differences. 6 (4): 515–517. doi:10.1016/0191-8869(85)90148-5. ISSN 0191-8869.
^ Mark J. Russ; James M. Gold (1987). "LSD-Like Flashbacks Associated with ECT". Convulsive therapy. 3 (4): 296–301. PMID 11940932.
^ R.D. Alarcon; W.A. Dickinson; H.H. Dohn (April 1982). "Flashback phenomena. Clinical and diagnostic dilemmas". The Journal of Nervous and Mental Disease. 170 (4): 217–223. doi:10.1097/00005053-198204000-00006. PMID 7062008.
^ ^a ^b Naditch MP, Fenwick S (1977). "LSD flashbacks and ego functioning". Journal of Abnormal Psychology. 86 (4): 352–9. doi:10.1037/0021-843X.86.4.352. PMID 757972.
^ Frankel, Fred H. (1994). "The Concept of Flashbacks in Historical Perspective". International Journal of Clinical and Experimental Hypnosis. 42 (4): 321–336. doi:10.1080/00207149408409362. ISSN 0020-7144.
^ Matefy, Robert E.; Hayes, Carla; Hirsch, Jerrold (1979). "Psychedelic drug flashbacks: Attentional deficits?". Journal of Abnormal Psychology. 88 (2): 212–215. doi:10.1037/0021-843X.88.2.212. ISSN 0021-843X.
^ R. McGee (May 1984). "Flashbacks and memory phenomena. A comment on "Flashback phenomena--clinical and diagnostic dilemmas"". The Journal of Nervous and Mental Disease. 172 (5): 273–278. doi:10.1097/00005053-198405000-00004. PMID 6716092.
^ R.J. Strassman (October 1984). "Adverse reactions to psychedelic drugs. A review of the literature". The Journal of Nervous and Mental Disease. 172 (10): 577–595. doi:10.1097/00005053-198410000-00001. PMID 6384428.
^ Edward, Brecher. "The Consumers Union Report on Licit and Illicit Drugs (1971): Chapter 51".
^ Abraham HD, Aldridge AM (1993). "Adverse consequences of lysergic acid diethylamide". Addiction. 88 (10): 1327–34. doi:10.1111/j.1360-0443.1993.tb02018.x. PMID 8251869.
^ Abraham HD, Aldridge AM (1993). "Adverse consequences of lysergic acid diethylamide". Addiction. 88 (10): 1327–34. doi:10.1111/j.1360-0443.1993.tb02018.x. PMID 8251869.
^ Halpern JH, Pope HG (2003). "Hallucinogen persisting perception disorder: what do we know after 50 years?". Drug Alcohol Depend. 69 (2): 109–19. doi:10.1016/S0376-8716(02)00306-X. PMID 12609692.
^ Halpern JH (2003). "Hallucinogens: an update". Curr Psychiatry Rep. 5 (5): 347–54. doi:10.1007/s11920-003-0067-4. PMID 13678554.
^ Li JH, Lin LF (November 1998). "Genetic toxicology of abused drugs: a brief review". Mutagenesis. 13 (6): 557–565. doi:10.1093/mutage/13.6.557. PMID 9862186.
^ "Gross behavioural changes in monkeys following administration of LSD-25, and development of tolerance to LSD-25 – Springer". Psychopharmacologia. 6: 303–306. doi:10.1007/BF00413161. Retrieved September 25, 2014.
^ Wolbach AB, Isbell H, Miner EJ (1962). "Cross tolerance between mescaline and LSD-25, with a comparison of the mescaline and LSD reactions". Psychopharmacologia. 3: 1–14. doi:10.1007/BF00413101. PMID 14007904.
^ Isbell H, Wolbach AB, Wikler A, Miner EJ (1961). "Cross Tolerance between LSD and Psilocybin". Psychopharmacologia. 2 (3): 147–59. doi:10.1007/BF00407974. PMID 13717955.
^ ^a ^b ^c Nichols DE (2004). "Hallucinogens". Pharmacology & Therapeutics. 101 (2): 131–81. doi:10.1016/j.pharmthera.2003.11.002. PMID 14761703.
^ McKenna DJ, Nazarali AJ, Himeno A, Saavedra JM (1989). "Chronic treatment with (+/-)DOI, a psychotomimetic 5-HT2 agonist, downregulates 5-HT2 receptors in rat brain". Neuropsychopharmacology. 2 (1): 81–87. doi:10.1016/0893-133X(89)90010-9. PMID 2803482.
^ Buckholtz NS, Zhou DF, Freedman DX, Potter WZ (1990). "Lysergic acid diethylamide (LSD) administration selectively downregulates serotonin2 receptors in rat brain". Neuropsychopharmacology. 3 (2): 137–148. PMID 1969270.
^ ^a ^b ^c LSD Toxicity Treatment & Management~treatment at eMedicine
^ Klock, John C.; Boerner, Udo; Becker, Charles E. (1974). "Coma, Hyperthermia and Bleeding Associated with Massive LSD Overdose: A Report of Eight Cases". The Western Journal of Medicine. 120 (3): 183–8. PMC 1129381. PMID 4816396.
^ Marona-Lewicka D, Thisted RA, Nichols DE (2005). "Distinct temporal phases in the behavioral pharmacology of LSD: Dopamine D2 receptor-mediated effects in the rat and implications for psychosis". Psychopharmacology. 180 (3): 427–435. doi:10.1007/s00213-005-2183-9. PMID 15723230.
^ Nichols, David (November 2012). "The End of a Chemistry Era... Dave Nichols Closes Shop". Retrieved September 24, 2013.
^ ^a ^b Aghajanian GK, Bing OH (1964). "Persistence of lysergic acid diethylamide in the plasma of human subjects" (PDF). Clinical Pharmacology and Therapeutics. 5: 611–614. PMID 14209776. Archived from the original (PDF) on March 27, 2009. Retrieved September 17, 2009. {{cite journal}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
^ "PDSP database". Archived from the original on May 17, 2013. Retrieved June 28, 2013. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
^ Nelson DL (February 2004). "5-HT5 receptors". Current drug targets. CNS and neurological disorders. 3 (1): 53–8. doi:10.2174/1568007043482606. PMID 14965244.
^ Moreno JL, et al. (2011). "Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists". Neurosci Lett. 493 (3): 76–79. doi:10.1016/j.neulet.2011.01.046. PMC 3064746. PMID 21276828.
^ Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, Miller KJ, Spedding M, Mailman RB (June 27, 2006). "Functional Selectivity and Classical Concepts of Quantitative Pharmacology". JPET. 320 (1): 1–13. doi:10.1124/jpet.106.104463. PMID 16803859.
^ BilZ0r. "The Neuropharmacology of Hallucinogens: a technical overview". Erowid, v3.1 (August 2005).
^ Svenningsson P, Nairn AC, Greengard P (2005). "DARPP-32 mediates the actions of multiple drugs of abuse". AAPS Journal. 7 (2): E353–E360. doi:10.1208/aapsj070235. PMC 2750972. PMID 16353915.
^ ^a ^b Borroto-Escuela DO, et al. (2014). "Hallucinogenic 5-HT2AR agonists LSD and DOI enhance dopamine D2R protomer recognition and signaling of D2-5-HT2A heteroreceptor complexes". Biochem Biophys Res Commun. 443 (1): 278–84. doi:10.1016/j.bbrc.2013.11.104. PMID 24309097.
^ ^a ^b ^c ^d UNC Health Care (January 26, 2017). "This is LSD Attached to a Brain Cell Serotonin Receptor (Update)". Phys.org. Phys.org. {{cite web}}: Missing or empty |url= (help)
^ ^a ^b ^c ^d Cell Press (January 26, 2017). "Structure of LSD and its receptor explains its potency". Science Daily. Science Daily. {{cite web}}: Missing or empty |url= (help)
^ ^a ^b ^c ^d ^e Wacker, Daniel; Wang, Sheng; McCorvy, John D.; Betz, Robin M.; Venkatakrishnan, A.J.; Levit, Anat; Lansu, Katherine; Schools, Zachary L.; Che, Tao; Nichols, David E.; Shoichet, Brian K.; Dror, Ron O.; Roth, Bryan L. (2017). "Crystal Structure of an LSD-Bound Human Serotonin Receptor". Cell. 168 (3): 377–389.e12. doi:10.1016/j.cell.2016.12.033. ISSN 0092-8674.
^ Papac DI, Foltz RL (May–June 1990). "Measurement of lysergic acid diethylamide (LSD) in human plasma by gas chromatography/negative ion chemical ionization mass spectrometry" (PDF). Journal of Analytical Toxicology. 14 (3): 189–190. doi:10.1093/jat/14.3.189. PMID 2374410. Retrieved September 17, 2009.
^ Monte AP, Marona-Lewicka D, Kanthasamy A, Sanders-Bush E, Nichols DE (March 1995). "Stereoselective LSD-like activity in a series of d-lysergic acid amides of (R)- and (S)-2-aminoalkanes". Journal of Medicinal Chemistry. 38 (6): 958–66. doi:10.1021/jm00006a015. PMID 7699712.
^ Nichols DE, Frescas S, Marona-Lewicka D, Kurrasch-Orbaugh DM (September 2002). "Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD)". Journal of Medicinal Chemistry. 45 (19): 4344–9. doi:10.1021/jm020153s. PMID 12213075.
^ "Erowid Morning Glory Vaults : Extraction of LSA (Method #1)". erowid.org. Retrieved September 25, 2014.
^ Kornfeld, Edmund C.; Fornefeld, E. J.; Kline, G. Bruce; Mann, Marjorie J.; Morrison, Dwight E.; Jones, Reuben G.; Woodward, R. B. (1956). "The Total Synthesis of Lysergic Acid". Journal of the American Chemical Society. 78 (13): 3087–3114. doi:10.1021/ja01594a039.
^ Inuki S, Oishi S, Fujii N, Ohno H (2008). "Total Synthesis of (±)-Lysergic Acid, Lysergol, and Isolysergol by Palladium-Catalyzed Domino Cyclization of Amino Allenes Bearing a Bromoindolyl Group". Organic Letters. 10 (22): 5239–5242. doi:10.1021/ol8022648. PMID 18956869.
^ Stoll, W.A. (1947). "Ein neues, in sehr kleinen Mengen wirsames Phantastikum". Arch. Neurol. 60. Schweiz: 483.
^ ^a ^b Erowid & Eduardo Hidalgo, Energy Control (Spain) (2009). "LSD Samples Analysis". Erowid. Retrieved February 8, 2010.
^ ^a ^b Henderson, Leigh A.; Glass, William J. (1994). LSD: Still with us after all these years. San Francisco: Jossey-Bass. ISBN 978-0-7879-4379-0.
^ Fire & Earth Erowid (2003). "LSD Analysis – Do we know what's in street acid?". Erowid. Retrieved February 8, 2010.
^ Li Z, McNally AJ, Wang H, Salamone SJ (October 1998). "Stability study of LSD under various storage conditions". J. Anal. Toxicol. 22 (6): 520–5. doi:10.1093/jat/22.6.520. PMID 9788528.
^ R. Baselt, Disposition of Toxic Drugs and Chemicals in Man, 8th edition, Biomedical Publications, Foster City, CA, 2008, pp. 871–874.
^ Papac DI, Foltz RL (1990). "Measurement of lysergic acid diethylamide (LSD) in human plasma by gas chromatography/negative ion chemical ionization mass spectrometry". J Anal Toxicol. 14: 189–90. doi:10.1093/jat/14.3.189. PMID 2374410.
^ Hofmann 1980, p. 15
^ Albert Hofmann; translated from the original German (LSD Ganz Persönlich) by J. Ott. MAPS-Volume 6, Number 69, Summer 1969
^ Nichols, David (May 24, 2003). "Hypothesis on Albert Hofmann's Famous 1943 "Bicycle Day"". Hofmann Foundation. Retrieved September 27, 2007.
^ Albert Hofmann. "LSD My Problem Child". Retrieved April 19, 2010.
^ Hofmann, Albert. "History Of LSD". Archived from the original on September 4, 2007. Retrieved September 27, 2007. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
^ DEA Public Affairs (November 16, 2001). "LSD: The Drug". Web.petabox.bibalex.org. Archived from the original on April 27, 1999. Retrieved November 27, 2010. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
^ "Brecher, Edward M; et al. (1972). "How LSD was popularized". Consumer Reports/Drug Library". Druglibrary.org. Retrieved June 20, 2012.
^ Anne Applebaum, "Did The Death Of Communism Take Koestler And Other Literary Figures With It?", The Huffington Post, January 26, 2010.
^ "Out-Of-Sight! SMiLE Timeline". Archived from the original on February 1, 2010. Retrieved October 30, 2011.
^ L. R. Veysey, The Communal Experience: Anarchist and Mystical Communities in Twentieth-Century America (Chicago IL, University of Chicago Press, 1978), ISBN 0-226-85458-2, p. 437.
^ ^a ^b ^c Jarnow, Jesse (2016). Heads: A Biography of Psychedelic America. Da Capo Press. ISBN 9780306822551.
^ United States Congress (October 24, 1968). "Staggers-Dodd Bill, Public Law 90-639" (PDF). Retrieved September 8, 2009.
^ Gasser, Peter (1994). "Psycholytic Therapy with MDMA and LSD in Switzerland". Retrieved September 8, 2009.
^ J. DeRogatis, Turn On Your Mind: Four Decades of Great Psychedelic Rock (Milwaukie, Michigan: Hal Leonard, 2003), ISBN 0-634-05548-8, pp. 8–9.
^ Gilliland, John (1969). "Show 41 – The Acid Test: Psychedelics and a sub-culture emerge in San Francisco. [Part 1] : UNT Digital Library" (audio). Pop Chronicles. Digital.library.unt.edu. Retrieved May 6, 2011.
^ M. Hicks, Sixties Rock: Garage, Psychedelic, and Other Satisfactions Music in American Life (Chicago, IL: University of Illinois Press, 2000), ISBN 0-252-06915-3, p. 60.
^ J. Mann, Turn on and Tune in: Psychedelics, Narcotics and Euphoriants (Royal Society of Chemistry, 2009), ISBN 1-84755-909-3, p. 87.
^ Joshua Clark Davis, The Business of Getting High: Head Shops, Countercultural Capitalism, and the Marijuana Legalization Movement. The Sixties: A Journal of Politics, Culture and Society, Summer 2015. Free full text
^ R. Rubin and J. P. Melnick, Immigration and American Popular Culture: an Introduction (New York, NY: New York University Press, 2007), ISBN 0-8147-7552-7, pp. 162–4.
^ P. Prown, H. P. Newquist and J. F. Eiche, Legends of Rock Guitar: the Essential Reference of Rock's Greatest Guitarists (London: Hal Leonard Corporation, 1997), ISBN 0-7935-4042-9, p. 48.
^ S. Borthwick and R. Moy, Popular Music Genres: an Introduction (Edinburgh: Edinburgh University Press, 2004), ISBN 0-7486-1745-0, pp. 52–4.
^ J. DeRogatis, Turn On Your Mind: Four Decades of Great Psychedelic Rock (Milwaukie, Michigan: Hal Leonard, 2003), ISBN 0-634-05548-8, p. 230.
^ Richie Unterberger, Samb Hicks, Jennifer Dempsey, "Music USA: the rough guide" (Rough Guides, 1999), ISBN 1-85828-421-X, p. 391.
^ G. St. John, Rave Culture and Religion (Abingdon: Routledge, 2004), ISBN 0-415-31449-6, p. 52.
^ Sheff, David (2000). All We Are Saying: The Last Major Interview with John Lennon and Yoko Ono. New York: St. Martin's Press. ISBN 0-312-25464-4. {{cite book}}: Invalid |ref=harv (help)
^ Thompson, Thomas (June 16, 1967). "The New Far-Out Beatles". Life. Chicago: Time Inc. p. 101. Retrieved December 8, 2016.
^ McCartney, Paul (June 19, 1967). "Interview with Paul McCartney". ITV Evening News (Interview). London: Independent Television News. {{cite interview}}: Unknown parameter |subjectlink= ignored (|subject-link= suggested) (help)
^ M. Campbell, Popular Music in America: And the Beat Goes on (Boston, MA: Cengage Learning, 3rd edn., 2008), ISBN 0-495-50530-7, pp. 212–3.
^ UN Convention on Psychotropic Substances, 1971 Final act of the United Nations Conference
^ ^a ^b Poisons Standard July 2016
^ Misuse of Drugs Act 1981 (2015) Slp.wa.gov.au
^ Canadian government (1996). "Controlled Drugs and Substances Act". Justice Laws. Canadian Department of Justice. Archived from the original on December 15, 2013. Retrieved December 15, 2013. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
^ Drugs and the law: Report of the inquiry into the Misuse of Drugs Act 1971 London: Police Foundation, 2000, Runciman Report
^ After the War on Drugs: Blueprint for Regulation Transform Drug Policy Foundation 2009
^ From "Archived copy". Archived from the original on October 5, 2009. Retrieved February 5, 2016. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)CS1 maint: archived copy as title (link): LSD is a Schedule I substance under the Controlled Substances Act.
^ LSD Toxicity at eMedicine
^ Neal v. United States, U.S. 284 (1996)., originating from U.S. v. Neal, 46 F.3d 1405 (7th Cir. 1995)
^ Ley de Narcomenudeo Archived November 30, 2010, at the Wayback Machine, El Pensador Template:Es icon, 17 October 2009
^ Mexico: The Law Against Small-Scale Drug Dealing. A Doubtful Venture, Jorge Hernández Tinajero & Carlos Zamudio Angles, Series on Legislative Reform of Drug Policies Nr. 3, November 2009
^ ^a ^b Parliament of the Czech Republic (1998), Explanatory Report to Act No. 112/1998 Coll., which amends the Act No. 140/1961 Coll., the Criminal Code, and the Act No. 200/1990 Coll., on misdemeanors (in Czech), Prague{{citation}}: CS1 maint: location missing publisher (link) "Podle čl. 36 Jednotné úmluvy o omamných látkách ze dne 31. března 1961 (č. 47/1965 Sb.) se signatáři zavazují k trestnímu postihu tam uvedených forem nakládání s drogami včetně jejich držby. Návrh upouští od dosavadní beztrestnosti držby omamných a psychotropních látek a jedů pro svoji potřebu. Dosavadní beztrestnost totiž eliminuje v řadě případů možnost postihu dealerů a distributorů drog."
^ Supreme Court of the Czech Republic (February 25, 2012), 6 Tdo 156/2010 [NS 7078/2010]
^ Government of the Czech Republic (2009), Regulation No. 467/2009 Coll., which defines for the purposes of the Criminal Code what is to be considered larger than small amount of narcotic and psychoactive substances and poisons (in Czech), Prague{{citation}}: CS1 maint: location missing publisher (link)
^ ^a ^b "La nueva tabla para consumo de drogas es una guía para jueces". Archived from the original on June 22, 2013.
^ "Dosis máximas de droga para consumo ya están vigentes" Archived July 6, 2013, at WebCite at El Comercio.com.
^ "Ecuador: Aprueban tenencia de drogas para consumo" Archived June 25, 2013, at the Wayback Machine at El Nuevo Herald
^ "Ecuador could regulate the drug industry".
^ ^a ^b DEA (2007). "LSD Manufacture – Illegal LSD Production". LSD in the United States. U.S. Department of Justice Drug Enforcement Administration. Archived from the original on August 29, 2007.
^ ^a ^b ^c Stafford, Peter (1992). "Chapter 1 – The LSD Family". Psychedelics Encyclopaedia (Third Expanded ed.). Ronin Publishing Inc. p. 62. ISBN 0-914171-51-8.
^ ^a ^b ^c Laing, Richard R.; Barry L. Beyerstein; Jay A. Siegel (2003). "Chapter 2.2 – Forms of the Drug". Hallucinogens: A Forensic Drug Handbook. Academic Press. pp. 39–41. ISBN 0-12-433951-4. {{cite book}}: External link in |chapterurl= (help); Unknown parameter |chapterurl= ignored (|chapter-url= suggested) (help)
^ Honig, David. Frequently Asked Questions via Erowid
^ "Street Terms: Drugs and the Drug Trade". Office of National Drug Control Policy. April 5, 2005. Retrieved January 31, 2007.
^ DEA (2008). "Photo Library (page 2)". US Drug Enforcement Administration. Archived from the original on June 23, 2008. Retrieved June 27, 2008. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
^ ^ Maclean, J.R.; Macdonald, D.C.; Ogden, F.; Wilby, E., "LSD-25 and mescaline as therapeutic adjuvants." In: Abramson, H., Ed., The Use of LSD in Psychotherapy and Alcoholism, Bobbs-Merrill: New York, 1967, pp. 407–426; Ditman, K.S.; Bailey, J.J., "Evaluating LSD as a psychotherapeutic agent," pp.74–80; Hoffer, A., "A program for the treatment of alcoholism: LSD, malvaria, and nicotinic acid," pp. 353–402.
^ ^ LSD: The Drug
^ Schou, Nicholas (2010). Orange Sunshine: The Brotherhood of Eternal Love and Its Quest to Spread Peace, Love, and Acid to the World. Thomas Dunne Books.
^ United States Drug Enforcement Administration (October 2005). "LSD BLOTTER ACID MIMIC CONTAINING 4-BROMO-2, 5-DIMETHOXY-AMPHETAMINE (DOB) SEIZED NEAR BURNS, OREGON" (PDF). Microgram Bulletin. 38 (10). Retrieved August 20, 2009.
^ United States Drug Enforcement Administration (November 2006). ""PURPLE" (COUGH SYRUP CONTAINING CODEINE AND OXYCODONE) IN WILKINSBURG, PENNSYLVANIA" (PDF). Microgram Bulletin. 39 (11). Retrieved August 20, 2009.
^ United States Drug Enforcement Administration (March 2008). "UNUSUAL "RICE KRISPIE TREAT"-LIKE BALLS CONTAINING PSILOCYBE MUSHROOM PARTS IN WARREN COUNTY, MISSOURI" (PDF). Microgram Bulletin. 41 (3). Retrieved August 20, 2009.
^ Iversen, Les (May 29, 2013). "Temporary Class Drug Order Report on 5-6APB and NBOMe compounds" (PDF). Advisory Council on the Misuse of Drugs. Gov.Uk. p. 14. Retrieved June 16, 2013.
^ United States Drug Enforcement Administration (March 2009). ""SPICE" – PLANT MATERIAL(S) LACED WITH SYNTHETIC CANNABINOIDS OR CANNABINOID MIMICKING COMPOUNDS" (PDF). Microgram Bulletin. 42 (3). Retrieved August 20, 2009.
^ United States Drug Enforcement Administration (November 2005). "BULK MARIJUANA IN HAZARDOUS PACKAGING IN CHICAGO, ILLINOIS" (PDF). Microgram Bulletin. 38 (11). Retrieved August 20, 2009.
^ United States Drug Enforcement Administration (December 2007). "SMALL HEROIN DISKS NEAR GREENSBORO, GEORGIA" (PDF). Microgram Bulletin. 40 (12). Retrieved August 20, 2009.
^ Erowid. "25I-NBOMe (2C-I-NBOMe) Fatalities / Deaths". Drug Website. Erowid. Retrieved February 28, 2016.
^ Hastings, Deborah (May 6, 2013). "New drug N-bomb hits the street, terrifying parents, troubling cops". New York Daily News. Retrieved May 7, 2013.
^ Feehan, Conor (January 21, 2016). "Powerful N-Bomb drug - responsible for spate of deaths internationally - responsible for hospitalisation of six in Cork". Irish Independent. Retrieved January 22, 2016.
^ Iversen, Les (May 29, 2013). "Temporary Class Drug Order Report on 5-6APB and NBOMe compounds" (PDF). Advisory Council on the Misuse of Drugs. Gov.Uk. Retrieved June 16, 2013.
^ "The Albert Hofmann Foundation". Hofmann Foundation. Retrieved September 27, 2007.
^ "LSD & Psilocybin-Assisted Therapy for Anxiety". Retrieved October 16, 2013.
^ DEA Public Affairs (November 16, 2001). "DEA – Publications – LSD in the US – The Drug". Web.petabox.bibalex.org. Archived from the original on April 27, 1999. Retrieved November 27, 2010. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
^ Bogenschutz MP (2013). "Studying the effects of classic hallucinogens in the treatment of alcoholism: Rationale, methodology, and current research with psilocybin". Current Drug Abuse Reviews. 6 (1): 17–29. doi:10.2174/15733998113099990002. PMID 23627783.
^ ^a ^b Passie T, Halpern JH, Stichtenoth DO, Emrich HM, Hintzen A (2008). "The pharmacology of lysergic acid diethylamide: A review". CNS Neuroscience & Therapeutics. 14 (4): 295–314. doi:10.1111/j.1755-5949.2008.00059.x. PMID 19040555.
^ Cohen, S. (1959). The therapeutic potential of LSD-25. A Pharmacologic Approach to the Study of the Mind, p251–258.
^ "Use of d-lysergic acid diethylamide in the treatment of alcoholism". Retrieved June 20, 2012.
^ "Use of d-Lysergic Acid Diethylamide in the Treatment of Alcoholism". Hofmann.org. November 14, 2003. Retrieved February 22, 2012.
^ Chwelos N, Blewett DB, Smith CM, Hoffer A (1959). "Use of d-lysergic acid diethylamide in the treatment of alcoholism". Quart. J. Stud. Alcohol. 20: 577–90. PMID 13810249.
^ Vollenweider, F. X.; Kometer, M (2010). "The neurobiology of psychedelic drugs: Implications for the treatment of mood disorders". Nature Reviews Neuroscience. 11 (9): 642–51. doi:10.1038/nrn2884. PMID 20717121.
^ Baumeister, D; Barnes, G; Giaroli, G; Tracy, D (2014). "Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles". Therapeutic Advances in Psychopharmacology. 4 (4): 156–69. doi:10.1177/2045125314527985. PMC 4104707. PMID 25083275.
^ "LSD-Assisted Psychotherapy". MAPS. Retrieved October 3, 2016.
^ Sessa B (2008). "Is it time to revisit the role of psychedelic drugs in enhancing human creativity?". J Psychopharmacol. 22 (8): 821–7. doi:10.1177/0269881108091597. PMID 18562421.
^ Janiger O, Dobkin de Rios M (1989). "LSD and creativity". J Psychoactive Drugs. 21 (1): 129–34. doi:10.1080/02791072.1989.10472150. PMID 2723891.
^ Stafford, Peter G.; B. H. Golightly (1967). LSD, the problem-solving psychedelic. ASIN B0006BPSA0.
^ McGlothlin W, Cohen S, McGlothlin MS (1967). "Long lasting effects of LSD on normals" (PDF). Archives of General Psychiatry. 17 (5): 521–532. doi:10.1001/archpsyc.1967.01730290009002. PMID 6054248. Archived from the original (PDF) on April 30, 2011. {{cite journal}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
^ "Psychiater Gasser bricht sein Schweigen". July 28, 2009.
^ LSD-Assisted Psychotherapy http://www.maps.org/research/psilo-lsd
^ Krebs, T. S.; Johansen, P.-O. (2012). "Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials". Journal of Psychopharmacology. 26 (7): 994–1002. doi:10.1177/0269881112439253. PMID 22406913.
^ Berlin pilot cluster headaches treatment with LSD study. LSD Alleviates 'Suicide Headaches' Archived January 10, 2012, at the Wayback Machine.
^ "Famous LSD users". The Good Drugs Guide. Retrieved October 20, 2008.
^ "People on psychedelics". Retrieved November 1, 2012.
^ Feynman, Richard P. (1985). Ralph Leighton (ed.). Surely You're Joking, Mr. Feynman!: Adventures of a Curious Character. W. W. Norton. ISBN 0-393-01921-7. OCLC 10925248.
^ Gleick, James (1992). Genius: The Life and Science of Richard Feynman. Pantheon Books. ISBN 0-679-40836-3. OCLC 243743850.
^ Alderson, Jeremy (April 20, 2010). "Q&A with Jerry Garcia: Portrait of an Artist as a Tripper". Relix Magazine. Archived from the original on May 21, 2010. Retrieved June 29, 2013. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
^ "The Bill Gates Interview". Playboy. July 1994.
^ Colman, Dan (October 2011). "Aldous Huxley's LSD Death Trip". Retrieved November 1, 2011.
^ Bosker, Bianca (October 21, 2011). "The Steve Jobs Reading List: The Books And Artists That Made The Man". The Huffington Post. Retrieved October 23, 2011.
^ Sheff 2000, p. 182.
^ "Lucy in the Sky with Diamonds LSD". snopes.com. Retrieved June 20, 2012.
^ Matus, Victorino (June 2004). "The Truth Behind "LSD"". The Weekly Standard.
^ Ann Harrison (January 16, 2006). "LSD: The Geek's Wonder Drug?". Wired. Wired. Retrieved March 11, 2008. Like Herbert, many scientists and engineers also report heightened states of creativity while using LSD. During a press conference on Friday, Hofmann revealed that he was told by Nobel-prize-winning chemist Kary Mullis that LSD had helped him develop the polymerase chain reaction that helps amplify specific DNA sequences.

External links

Drug Profiles: LSD European Monitoring Centre for Drugs and Drug Addiction
LSD-25 at Erowid
The Lycaeum Archive: LSD
LSD entry in TiHKAL • info
InfoFacts – Hallucinogens NIDA
Scholarly bibliography on the histories of LSD use
LSD Returns-For Psychotherapeutics (Scientific American Magazine article)
U.S. National Library of Medicine: Drug Information Portal – Lysergic acid diethylamide
My LSD Trip: a non-cop, non-hippie report of the unvarnished facts, by Robert Gannon, Popular Science Magazine, December 1967.
WWW Psychedelic Bibliography, MAPS – large database of scientific publications on LSD and other psychedelics, fulltext PDFs

Documentaries

Hofmann's Potion a documentary on the origins of LSD
Power & Control LSD in The Sixties on YouTube, documentary film directed by Aron Ranen, 2006
Inside LSD National Geographic Channel, 2009

Template:TiHKAL

[1] "Definition of "amide"". Collins English Dictionary. Retrieved January 31, 2015.

[2] "American Heritage Dictionary Entry: amide". Ahdictionary.com. Retrieved January 31, 2015.

[3] "amide - definition of amide in English from the Oxford dictionary". Oxforddictionaries.com. Retrieved January 31, 2015.

[4] Halpern, John H.; Suzuki, Joji; Huertas,, Pedro E.; Passie, Torsten (June 7, 2014). Price, Lawrence H.; Stolerman, Ian P. (eds.). Encyclopedia of Psychopharmacology A Springer Live Reference. Heidelberg, Germany: Springer-Verlag Berlin Heidelberg. pp. 1–5. ISBN 978-3-642-27772-6. Retrieved April 24, 2015. Hallucinogen abuse and dependence are known complications resulting from the illicit use of drugs in this category, such as LSD and psilocybin. Users do not experience withdrawal symptoms, but the general criteria for substance abuse and dependence otherwise apply. Dependence is estimated in approximately 2 % of recent-onset users in the United States.{{cite book}}: CS1 maint: extra punctuation (link)

[NHM-MDMA-5] Malenka RC, Nestler EJ, Hyman SE (2009). "Chapter 15: Reinforcement and Addictive Disorders". In Sydor A, Brown RY (eds.). Molecular Neuropharmacology: A Foundation for Clinical Neuroscience (2nd ed.). New York: McGraw-Hill Medical. p. 375. ISBN 9780071481274. Several other classes of drugs are categorized as drugs of abuse but rarely produce compulsive use. These include psychedelic agents, such as lysergic acid diethylamide (LSD), which are used for their ability to produce perceptual distortions at low and moderate doses. The use of these drugs is associated with the rapid development of tolerance and the absence of positive reinforcement (Chapter 6). Partial agonist effects at 5HT2A receptors are implicated in the psychedelic actions of LSD and related hallucinogens. 3,4-Methylenedioxymethamphetamine (MDMA), commonly called ecstasy, is an amphetamine derivative. It produces a combination of psychostimulant-like and weak LSD-like effects at low doses. Unlike LSD, MDMA is reinforcing—most likely because of its interactions with dopamine systems—and accordingly is subject to compulsive abuse. The weak psychedelic effects of MDMA appear to result from its amphetamine-like actions on the serotonin reuptake transporter, by means of which it causes transporter-dependent serotonin efflux. MDMA has been proven to produce lesions of serotonin neurons in animals and humans.

[pmid26108222-6] ^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k ^l ^m Dolder PC, Schmid Y, Haschke M, Rentsch KM, Liechti ME (2015). "Pharmacokinetics and Concentration-Effect Relationship of Oral LSD in Humans". Int. J. Neuropsychopharmacol. 19 (1): pyv072. doi:10.1093/ijnp/pyv072. PMC 4772267. PMID 26108222.

[Passie-2008-7] Passie T, Halpern JH, Stichtenoth DO, Emrich HM, Hintzen A (2008). "The Pharmacology of Lysergic Acid Diethylamide: a Review". CNS Neuroscience & Therapeutics. 14 (4): 295–314. doi:10.1111/j.1755-5949.2008.00059.x. PMID 19040555.

[8] Neinstein, Lawrence S. (2008). Adolescent Health Care: A Practical Guide. Lippincott Williams & Wilkins. p. 931. ISBN 9780781792561.

[pmid27392130-9] ^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j Mucke HA (2016). "From Psychiatry to Flower Power and Back Again: The Amazing Story of Lysergic Acid Diethylamide". Assay Drug Dev Technol. 14: 276–281. doi:10.1089/adt.2016.747. PMID 27392130.

[10] Kranzler, Henry R.; Ciraulo, Domenic A. (April 2, 2007). Clinical Manual of Addiction Psychopharmacology. American Psychiatric Pub. p. 216. ISBN 9781585626632.

[NIH2016-11] "What are hallucinogens?". National Institute of Drug Abuse. January 2016. Retrieved April 24, 2016.

[pmid17105338-12] Lüscher C, Ungless MA (November 2006). "The Mechanistic Classification of Addictive Drugs". PLoS Med. 3 (11): e437. doi:10.1371/journal.pmed.0030437. PMC 1635740. PMID 17105338.{{cite journal}}: CS1 maint: unflagged free DOI (link)

[tihkal-13] ^ ^a ^b ^c ^d ^e ^f ^g Alexander and Ann Shulgin. "LSD", in TiHKAL (Berkeley: Transform Press, 1997). ISBN 0-9630096-9-9.

[greiner-14] Greiner T, Burch NR, Edelberg R (1958). "Psychopathology and psychophysiology of minimal LSD-25 dosage; a preliminary dosage-response spectrum". AMA Arch Neurol Psychiatry. 79 (2): 208–10. doi:10.1001/archneurpsyc.1958.02340020088016. PMID 13497365.

[problem-child-15] Hofmann, Albert. LSD—My Problem Child (McGraw-Hill, 1980). ISBN 0-07-029325-2.

[16] "Hallucinogenic effects of LSD discovered". The History Channel.

[17] Arthur Stoll and Albert Hofmann LSD Patent April 30, 1943 in Switzerland and March 23, 1948 in the United States.

[18] "LSD: cultural revolution and medical advances". Royal Society of Chemistry. Retrieved September 27, 2007.

[Nutt2009-19] Nutt, David J.; King, Leslie A.; Nichols, David E. (August 1, 2013). "Effects of Schedule I drug laws on neuroscience research and treatment innovation". Nature Reviews Neuroscience. 14 (8): 577–585. doi:10.1038/nrn3530. ISSN 1471-003X. PMID 23756634.

[20] "Scientists study possible health benefits of LSD and ecstasy | Science | The Guardian". July 23, 2016. Archived from the original on July 23, 2016. Retrieved 2016-07-23. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)

[21] "DrugFacts: Hallucinogens - LSD, Peyote, Psilocybin, and PCP". National Institute on Drug Abuse. December 2014. Retrieved February 17, 2015.

[22] Alcohol and Drugs in North America: A Historical Encyclopedia, by David M. Fahey and Jon S. Miller, Editors, ISBN 978-1-59884-478-8, page 375

[23] San Francisco Chronicle September 20, 1966 Page One

[Grof1979-24] Grof, Stanislav; Joan Halifax Grof (1979). Realms of the Human Unconscious (Observations from LSD Research). London: Souvenir Press (E & A) Ltd. pp. 13–14. ISBN 0-285-64882-9.

[NIDA-25] NIDA InfoFacts: Hallucinogens - LSD, Peyote, Psilocybin, and PCP The National Institute on Drug Abuse (NIDA). Revised 06/09

[Schiff-26] Schiff PL (2006). "Ergot and its alkaloids". American Journal of Pharmaceutical Education. 70 (5): 98. doi:10.5688/aj700598. PMC 1637017. PMID 17149427.

[MedlinePlus-27] Rogge, Timothy (May 21, 2014), Substance use - LSD, MedlinePlus, U.S. National Library of Medicine, retrieved July 14, 2016

[CESAR-28] CESAR (October 29, 2013), LSD, Center for Substance Abuse Research, University of Maryland, archived from the original on July 15, 2016, retrieved July 14, 2016 {{citation}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)

[linton-langs-29] Linton Harriet B.; Langs Robert J. (1962). "Subjective Reactions to Lysergic Acid Diethylamide (LSD-25)" (PDF). Arch. Gen. Psychiatry. 6 (5): 352–68. doi:10.1001/archpsyc.1962.01710230020003.

[30] Albert Hofmann. "5. From Remedy to Inebriant". LSD: My Problem Child. ...taste of metal on the palate.

[31] Katz MM, Waskow IE, Olsson J (1968). "Characterizing the psychological state produced by LSD" (PDF). J Abnorm Psychol. 73 (1): 1–14. doi:10.1037/h0020114. PMID 5639999.

[32] See, e.g., Gerald Oster's article "Moiré patterns and visual hallucinations". Psychedelic Rev. No. 7 (1966): 33–40.

[33] Nutt, D; King, LA; Saulsbury, W; Blakemore, C (March 24, 2007). "Development of a rational scale to assess the harm of drugs of potential misuse". Lancet. 369 (9566): 1047–53. doi:10.1016/s0140-6736(07)60464-4. PMID 17382831.

[34] Nutt, David J.; King, Leslie A.; Phillips, Lawrence D. (November 6, 2010). "Drug harms in the UK: a multicriteria decision analysis". Lancet. 376 (9752): 1558–1565. doi:10.1016/S0140-6736(10)61462-6. ISSN 1474-547X. PMID 21036393.

[Murray-35] Murray RM, Paparelli A, Morrison PD, Marconi A, Di Forti M (October 2013), "What can we learn about schizophrenia from studying the human model, drug-induced psychosis?", American Journal of Medical Genetics Part B, 162 (7, Special Issue: Identifying the Origins of Mental Illness: A Festschrift in Honor of Ming T. Tsuang): 661–670, doi:10.1002/ajmg.b.32177

[36] "Is Military Research Hazardous to Veterans Health? Lessons Spanning Half A Century, part F. HALLUCINOGENS". December 8, 1994 John D. Rockefeller IV, West Virginia: 103rd Congress, 2nd Session-S. Prt. 103-97; Staff Report prepared for the committee on veterans' affairs. December 8, 1994.{{cite web}}: CS1 maint: location (link)

[37] Middlefell R (March 1967). "The effects of LSD on body sway suggestibility in a group of hospital patients" (PDF). Br J Psychiatry. 113 (496): 277–80. doi:10.1192/bjp.113.496.277. PMID 6029626.

[38] Sjoberg BM, Hollister LE (November 1965). "The effects of psychotomimetic drugs on primary suggestibility". Psychopharmacologia. 8 (4): 251–62. doi:10.1007/BF00407857. PMID 5885648.

[autogenerated92-39] Lerner AG, Gelkopf M, Skladman I, Oyffe I, Finkel B, Sigal M, Weizman A (2002). "Flashback and Hallucinogen Persisting Perception Disorder: Clinical aspects and pharmacological treatment approach". The Israel Journal of Psychiatry and Related Sciences. 39 (2): 92–9. PMID 12227234.

[40] Halpern JH, Pope HG (2003). "Hallucinogen persisting perception disorder: What do we know after 50 years?". Drug and Alcohol Dependence. 69 (2): 109–19. doi:10.1016/S0376-8716(02)00306-X. PMID 12609692.

[Halpern2003-41] Halpern, J (2003). "Hallucinogen persisting perception disorder: what do we know after 50 years?". Drug and Alcohol Dependence. 69 (2): 109–119. doi:10.1016/S0376-8716(02)00306-X. ISSN 0376-8716. PMID 12609692.

[Blumenfield-42] Blumenfield M (1971). "Flashback phenomena in basic trainees who enter the US Air Force". Military Medicine. 136 (1): 39–41. PMID 5005369.

[HemsleyWard1985-43] Hemsley, D.R.; Ward, E.S. (1985). "Individual differences in reaction to the abuse of LSD". Personality and Individual Differences. 6 (4): 515–517. doi:10.1016/0191-8869(85)90148-5. ISSN 0191-8869.

[44] Mark J. Russ; James M. Gold (1987). "LSD-Like Flashbacks Associated with ECT". Convulsive therapy. 3 (4): 296–301. PMID 11940932.

[45] R.D. Alarcon; W.A. Dickinson; H.H. Dohn (April 1982). "Flashback phenomena. Clinical and diagnostic dilemmas". The Journal of Nervous and Mental Disease. 170 (4): 217–223. doi:10.1097/00005053-198204000-00006. PMID 7062008.

[Nadich-46] Naditch MP, Fenwick S (1977). "LSD flashbacks and ego functioning". Journal of Abnormal Psychology. 86 (4): 352–9. doi:10.1037/0021-843X.86.4.352. PMID 757972.

[Frankel1994-47] Frankel, Fred H. (1994). "The Concept of Flashbacks in Historical Perspective". International Journal of Clinical and Experimental Hypnosis. 42 (4): 321–336. doi:10.1080/00207149408409362. ISSN 0020-7144.

[MatefyHayes1979-48] Matefy, Robert E.; Hayes, Carla; Hirsch, Jerrold (1979). "Psychedelic drug flashbacks: Attentional deficits?". Journal of Abnormal Psychology. 88 (2): 212–215. doi:10.1037/0021-843X.88.2.212. ISSN 0021-843X.

[49] R. McGee (May 1984). "Flashbacks and memory phenomena. A comment on "Flashback phenomena--clinical and diagnostic dilemmas"". The Journal of Nervous and Mental Disease. 172 (5): 273–278. doi:10.1097/00005053-198405000-00004. PMID 6716092.

[50] R.J. Strassman (October 1984). "Adverse reactions to psychedelic drugs. A review of the literature". The Journal of Nervous and Mental Disease. 172 (10): 577–595. doi:10.1097/00005053-198410000-00001. PMID 6384428.

[51] Edward, Brecher. "The Consumers Union Report on Licit and Illicit Drugs (1971): Chapter 51".

[52] Abraham HD, Aldridge AM (1993). "Adverse consequences of lysergic acid diethylamide". Addiction. 88 (10): 1327–34. doi:10.1111/j.1360-0443.1993.tb02018.x. PMID 8251869.

[53] Abraham HD, Aldridge AM (1993). "Adverse consequences of lysergic acid diethylamide". Addiction. 88 (10): 1327–34. doi:10.1111/j.1360-0443.1993.tb02018.x. PMID 8251869.

[54] Halpern JH, Pope HG (2003). "Hallucinogen persisting perception disorder: what do we know after 50 years?". Drug Alcohol Depend. 69 (2): 109–19. doi:10.1016/S0376-8716(02)00306-X. PMID 12609692.

[55] Halpern JH (2003). "Hallucinogens: an update". Curr Psychiatry Rep. 5 (5): 347–54. doi:10.1007/s11920-003-0067-4. PMID 13678554.

[56] Li JH, Lin LF (November 1998). "Genetic toxicology of abused drugs: a brief review". Mutagenesis. 13 (6): 557–565. doi:10.1093/mutage/13.6.557. PMID 9862186.

[springer-57] "Gross behavioural changes in monkeys following administration of LSD-25, and development of tolerance to LSD-25 – Springer". Psychopharmacologia. 6: 303–306. doi:10.1007/BF00413161. Retrieved September 25, 2014.

[isbell_mescaline-58] Wolbach AB, Isbell H, Miner EJ (1962). "Cross tolerance between mescaline and LSD-25, with a comparison of the mescaline and LSD reactions". Psychopharmacologia. 3: 1–14. doi:10.1007/BF00413101. PMID 14007904.

[isbell_psilocybin-59] Isbell H, Wolbach AB, Wikler A, Miner EJ (1961). "Cross Tolerance between LSD and Psilocybin". Psychopharmacologia. 2 (3): 147–59. doi:10.1007/BF00407974. PMID 13717955.

[nichols-60] Nichols DE (2004). "Hallucinogens". Pharmacology & Therapeutics. 101 (2): 131–81. doi:10.1016/j.pharmthera.2003.11.002. PMID 14761703.

[61] McKenna DJ, Nazarali AJ, Himeno A, Saavedra JM (1989). "Chronic treatment with (+/-)DOI, a psychotomimetic 5-HT2 agonist, downregulates 5-HT2 receptors in rat brain". Neuropsychopharmacology. 2 (1): 81–87. doi:10.1016/0893-133X(89)90010-9. PMID 2803482.

[62] Buckholtz NS, Zhou DF, Freedman DX, Potter WZ (1990). "Lysergic acid diethylamide (LSD) administration selectively downregulates serotonin2 receptors in rat brain". Neuropsychopharmacology. 3 (2): 137–148. PMID 1969270.

[Medscape-63] LSD Toxicity Treatment & Management~treatment at eMedicine

[64] Klock, John C.; Boerner, Udo; Becker, Charles E. (1974). "Coma, Hyperthermia and Bleeding Associated with Massive LSD Overdose: A Report of Eight Cases". The Western Journal of Medicine. 120 (3): 183–8. PMC 1129381. PMID 4816396.

[nichols_closes_shop-65] Marona-Lewicka D, Thisted RA, Nichols DE (2005). "Distinct temporal phases in the behavioral pharmacology of LSD: Dopamine D2 receptor-mediated effects in the rat and implications for psychosis". Psychopharmacology. 180 (3): 427–435. doi:10.1007/s00213-005-2183-9. PMID 15723230.

[66] Nichols, David (November 2012). "The End of a Chemistry Era... Dave Nichols Closes Shop". Retrieved September 24, 2013.

[Aghajanian-67] Aghajanian GK, Bing OH (1964). "Persistence of lysergic acid diethylamide in the plasma of human subjects" (PDF). Clinical Pharmacology and Therapeutics. 5: 611–614. PMID 14209776. Archived from the original (PDF) on March 27, 2009. Retrieved September 17, 2009. {{cite journal}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)

[68] "PDSP database". Archived from the original on May 17, 2013. Retrieved June 28, 2013. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)

[69] Nelson DL (February 2004). "5-HT5 receptors". Current drug targets. CNS and neurological disorders. 3 (1): 53–8. doi:10.2174/1568007043482606. PMID 14965244.

[70] Moreno JL, et al. (2011). "Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists". Neurosci Lett. 493 (3): 76–79. doi:10.1016/j.neulet.2011.01.046. PMC 3064746. PMID 21276828.

[71] Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, Miller KJ, Spedding M, Mailman RB (June 27, 2006). "Functional Selectivity and Classical Concepts of Quantitative Pharmacology". JPET. 320 (1): 1–13. doi:10.1124/jpet.106.104463. PMID 16803859.

[72] BilZ0r. "The Neuropharmacology of Hallucinogens: a technical overview". Erowid, v3.1 (August 2005).

[73] Svenningsson P, Nairn AC, Greengard P (2005). "DARPP-32 mediates the actions of multiple drugs of abuse". AAPS Journal. 7 (2): E353–E360. doi:10.1208/aapsj070235. PMC 2750972. PMID 16353915.

[pmid24309097-74] Borroto-Escuela DO, et al. (2014). "Hallucinogenic 5-HT2AR agonists LSD and DOI enhance dopamine D2R protomer recognition and signaling of D2-5-HT2A heteroreceptor complexes". Biochem Biophys Res Commun. 443 (1): 278–84. doi:10.1016/j.bbrc.2013.11.104. PMID 24309097.

[Phys.org2017-75] UNC Health Care (January 26, 2017). "This is LSD Attached to a Brain Cell Serotonin Receptor (Update)". Phys.org. Phys.org. {{cite web}}: Missing or empty |url= (help)

[ScienceDaily2017b-76] Cell Press (January 26, 2017). "Structure of LSD and its receptor explains its potency". Science Daily. Science Daily. {{cite web}}: Missing or empty |url= (help)

[WackerWang2017-77] Wacker, Daniel; Wang, Sheng; McCorvy, John D.; Betz, Robin M.; Venkatakrishnan, A.J.; Levit, Anat; Lansu, Katherine; Schools, Zachary L.; Che, Tao; Nichols, David E.; Shoichet, Brian K.; Dror, Ron O.; Roth, Bryan L. (2017). "Crystal Structure of an LSD-Bound Human Serotonin Receptor". Cell. 168 (3): 377–389.e12. doi:10.1016/j.cell.2016.12.033. ISSN 0092-8674.

[Papac-78] Papac DI, Foltz RL (May–June 1990). "Measurement of lysergic acid diethylamide (LSD) in human plasma by gas chromatography/negative ion chemical ionization mass spectrometry" (PDF). Journal of Analytical Toxicology. 14 (3): 189–190. doi:10.1093/jat/14.3.189. PMID 2374410. Retrieved September 17, 2009.

[synth1-79] Monte AP, Marona-Lewicka D, Kanthasamy A, Sanders-Bush E, Nichols DE (March 1995). "Stereoselective LSD-like activity in a series of d-lysergic acid amides of (R)- and (S)-2-aminoalkanes". Journal of Medicinal Chemistry. 38 (6): 958–66. doi:10.1021/jm00006a015. PMID 7699712.

[synth2-80] Nichols DE, Frescas S, Marona-Lewicka D, Kurrasch-Orbaugh DM (September 2002). "Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD)". Journal of Medicinal Chemistry. 45 (19): 4344–9. doi:10.1021/jm020153s. PMID 12213075.

[erowid-81] "Erowid Morning Glory Vaults : Extraction of LSA (Method #1)". erowid.org. Retrieved September 25, 2014.

[82] Kornfeld, Edmund C.; Fornefeld, E. J.; Kline, G. Bruce; Mann, Marjorie J.; Morrison, Dwight E.; Jones, Reuben G.; Woodward, R. B. (1956). "The Total Synthesis of Lysergic Acid". Journal of the American Chemical Society. 78 (13): 3087–3114. doi:10.1021/ja01594a039.

[83] Inuki S, Oishi S, Fujii N, Ohno H (2008). "Total Synthesis of (±)-Lysergic Acid, Lysergol, and Isolysergol by Palladium-Catalyzed Domino Cyclization of Amino Allenes Bearing a Bromoindolyl Group". Organic Letters. 10 (22): 5239–5242. doi:10.1021/ol8022648. PMID 18956869.

[84] Stoll, W.A. (1947). "Ein neues, in sehr kleinen Mengen wirsames Phantastikum". Arch. Neurol. 60. Schweiz: 483.

[LSD_Samples_Analysis-85] Erowid & Eduardo Hidalgo, Energy Control (Spain) (2009). "LSD Samples Analysis". Erowid. Retrieved February 8, 2010.

[henderson-glass-86] Henderson, Leigh A.; Glass, William J. (1994). LSD: Still with us after all these years. San Francisco: Jossey-Bass. ISBN 978-0-7879-4379-0.

[87] Fire & Earth Erowid (2003). "LSD Analysis – Do we know what's in street acid?". Erowid. Retrieved February 8, 2010.

[88] Li Z, McNally AJ, Wang H, Salamone SJ (October 1998). "Stability study of LSD under various storage conditions". J. Anal. Toxicol. 22 (6): 520–5. doi:10.1093/jat/22.6.520. PMID 9788528.

[89] R. Baselt, Disposition of Toxic Drugs and Chemicals in Man, 8th edition, Biomedical Publications, Foster City, CA, 2008, pp. 871–874.

[90] Papac DI, Foltz RL (1990). "Measurement of lysergic acid diethylamide (LSD) in human plasma by gas chromatography/negative ion chemical ionization mass spectrometry". J Anal Toxicol. 14: 189–90. doi:10.1093/jat/14.3.189. PMID 2374410.

[91] Hofmann 1980, p. 15

[92] Albert Hofmann; translated from the original German (LSD Ganz Persönlich) by J. Ott. MAPS-Volume 6, Number 69, Summer 1969

[hyponichols-93] Nichols, David (May 24, 2003). "Hypothesis on Albert Hofmann's Famous 1943 "Bicycle Day"". Hofmann Foundation. Retrieved September 27, 2007.

[94] Albert Hofmann. "LSD My Problem Child". Retrieved April 19, 2010.

[histlsd-95] Hofmann, Albert. "History Of LSD". Archived from the original on September 4, 2007. Retrieved September 27, 2007. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)

[96] DEA Public Affairs (November 16, 2001). "LSD: The Drug". Web.petabox.bibalex.org. Archived from the original on April 27, 1999. Retrieved November 27, 2010. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)

[97] "Brecher, Edward M; et al. (1972). "How LSD was popularized". Consumer Reports/Drug Library". Druglibrary.org. Retrieved June 20, 2012.

[98] Anne Applebaum, "Did The Death Of Communism Take Koestler And Other Literary Figures With It?", The Huffington Post, January 26, 2010.

[99] "Out-Of-Sight! SMiLE Timeline". Archived from the original on February 1, 2010. Retrieved October 30, 2011.

[100] L. R. Veysey, The Communal Experience: Anarchist and Mystical Communities in Twentieth-Century America (Chicago IL, University of Chicago Press, 1978), ISBN 0-226-85458-2, p. 437.

[Jarnow-101] Jarnow, Jesse (2016). Heads: A Biography of Psychedelic America. Da Capo Press. ISBN 9780306822551.

[102] United States Congress (October 24, 1968). "Staggers-Dodd Bill, Public Law 90-639" (PDF). Retrieved September 8, 2009.

[103] Gasser, Peter (1994). "Psycholytic Therapy with MDMA and LSD in Switzerland". Retrieved September 8, 2009.

[DeRogatispp8-9-104] J. DeRogatis, Turn On Your Mind: Four Decades of Great Psychedelic Rock (Milwaukie, Michigan: Hal Leonard, 2003), ISBN 0-634-05548-8, pp. 8–9.

[pc41-105] Gilliland, John (1969). "Show 41 – The Acid Test: Psychedelics and a sub-culture emerge in San Francisco. [Part 1] : UNT Digital Library" (audio). Pop Chronicles. Digital.library.unt.edu. Retrieved May 6, 2011.

[Hicks2000p60-106] M. Hicks, Sixties Rock: Garage, Psychedelic, and Other Satisfactions Music in American Life (Chicago, IL: University of Illinois Press, 2000), ISBN 0-252-06915-3, p. 60.

[Mann2009p87-107] J. Mann, Turn on and Tune in: Psychedelics, Narcotics and Euphoriants (Royal Society of Chemistry, 2009), ISBN 1-84755-909-3, p. 87.

[108] Joshua Clark Davis, The Business of Getting High: Head Shops, Countercultural Capitalism, and the Marijuana Legalization Movement. The Sixties: A Journal of Politics, Culture and Society, Summer 2015. Free full text

[109] R. Rubin and J. P. Melnick, Immigration and American Popular Culture: an Introduction (New York, NY: New York University Press, 2007), ISBN 0-8147-7552-7, pp. 162–4.

[110] P. Prown, H. P. Newquist and J. F. Eiche, Legends of Rock Guitar: the Essential Reference of Rock's Greatest Guitarists (London: Hal Leonard Corporation, 1997), ISBN 0-7935-4042-9, p. 48.

[111] S. Borthwick and R. Moy, Popular Music Genres: an Introduction (Edinburgh: Edinburgh University Press, 2004), ISBN 0-7486-1745-0, pp. 52–4.

[112] J. DeRogatis, Turn On Your Mind: Four Decades of Great Psychedelic Rock (Milwaukie, Michigan: Hal Leonard, 2003), ISBN 0-634-05548-8, p. 230.

[113] Richie Unterberger, Samb Hicks, Jennifer Dempsey, "Music USA: the rough guide" (Rough Guides, 1999), ISBN 1-85828-421-X, p. 391.

[114] G. St. John, Rave Culture and Religion (Abingdon: Routledge, 2004), ISBN 0-415-31449-6, p. 52.

[115] Sheff, David (2000). All We Are Saying: The Last Major Interview with John Lennon and Yoko Ono. New York: St. Martin's Press. ISBN 0-312-25464-4. {{cite book}}: Invalid |ref=harv (help)

[life-116] Thompson, Thomas (June 16, 1967). "The New Far-Out Beatles". Life. Chicago: Time Inc. p. 101. Retrieved December 8, 2016.

[itv-117] McCartney, Paul (June 19, 1967). "Interview with Paul McCartney". ITV Evening News (Interview). London: Independent Television News. {{cite interview}}: Unknown parameter |subjectlink= ignored (|subject-link= suggested) (help)

[118] M. Campbell, Popular Music in America: And the Beat Goes on (Boston, MA: Cengage Learning, 3rd edn., 2008), ISBN 0-495-50530-7, pp. 212–3.

[119] UN Convention on Psychotropic Substances, 1971 Final act of the United Nations Conference

[Poisons_Standard-120] Poisons Standard July 2016

[121] Misuse of Drugs Act 1981 (2015) Slp.wa.gov.au

[cdasa-122] Canadian government (1996). "Controlled Drugs and Substances Act". Justice Laws. Canadian Department of Justice. Archived from the original on December 15, 2013. Retrieved December 15, 2013. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)

[123] Drugs and the law: Report of the inquiry into the Misuse of Drugs Act 1971 London: Police Foundation, 2000, Runciman Report

[124] After the War on Drugs: Blueprint for Regulation Transform Drug Policy Foundation 2009

[125] From "Archived copy". Archived from the original on October 5, 2009. Retrieved February 5, 2016. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)CS1 maint: archived copy as title (link): LSD is a Schedule I substance under the Controlled Substances Act.

[126] LSD Toxicity at eMedicine

[127] Neal v. United States, U.S. 284 (1996)., originating from U.S. v. Neal, 46 F.3d 1405 (7th Cir. 1995)

[128] Ley de Narcomenudeo Archived November 30, 2010, at the Wayback Machine, El Pensador Template:Es icon, 17 October 2009

[129] Mexico: The Law Against Small-Scale Drug Dealing. A Doubtful Venture, Jorge Hernández Tinajero & Carlos Zamudio Angles, Series on Legislative Reform of Drug Policies Nr. 3, November 2009

[Cz_expl_rep-130] Parliament of the Czech Republic (1998), Explanatory Report to Act No. 112/1998 Coll., which amends the Act No. 140/1961 Coll., the Criminal Code, and the Act No. 200/1990 Coll., on misdemeanors (in Czech), Prague{{citation}}: CS1 maint: location missing publisher (link) "Podle čl. 36 Jednotné úmluvy o omamných látkách ze dne 31. března 1961 (č. 47/1965 Sb.) se signatáři zavazují k trestnímu postihu tam uvedených forem nakládání s drogami včetně jejich držby. Návrh upouští od dosavadní beztrestnosti držby omamných a psychotropních látek a jedů pro svoji potřebu. Dosavadní beztrestnost totiž eliminuje v řadě případů možnost postihu dealerů a distributorů drog."

[131] Supreme Court of the Czech Republic (February 25, 2012), 6 Tdo 156/2010 [NS 7078/2010]

[Cz_reg-132] Government of the Czech Republic (2009), Regulation No. 467/2009 Coll., which defines for the purposes of the Criminal Code what is to be considered larger than small amount of narcotic and psychoactive substances and poisons (in Czech), Prague{{citation}}: CS1 maint: location missing publisher (link)

[telegrafo-133] "La nueva tabla para consumo de drogas es una guía para jueces". Archived from the original on June 22, 2013.

[134] "Dosis máximas de droga para consumo ya están vigentes" Archived July 6, 2013, at WebCite at El Comercio.com.

[135] "Ecuador: Aprueban tenencia de drogas para consumo" Archived June 25, 2013, at the Wayback Machine at El Nuevo Herald

[136] "Ecuador could regulate the drug industry".

[DEA-pub-137] DEA (2007). "LSD Manufacture – Illegal LSD Production". LSD in the United States. U.S. Department of Justice Drug Enforcement Administration. Archived from the original on August 29, 2007.

[Stafford1992-138] Stafford, Peter (1992). "Chapter 1 – The LSD Family". Psychedelics Encyclopaedia (Third Expanded ed.). Ronin Publishing Inc. p. 62. ISBN 0-914171-51-8.

[Laing2003-139] Laing, Richard R.; Barry L. Beyerstein; Jay A. Siegel (2003). "Chapter 2.2 – Forms of the Drug". Hallucinogens: A Forensic Drug Handbook. Academic Press. pp. 39–41. ISBN 0-12-433951-4. {{cite book}}: External link in |chapterurl= (help); Unknown parameter |chapterurl= ignored (|chapter-url= suggested) (help)

[erowid-faq-140] Honig, David. Frequently Asked Questions via Erowid

[141] "Street Terms: Drugs and the Drug Trade". Office of National Drug Control Policy. April 5, 2005. Retrieved January 31, 2007.

[142] DEA (2008). "Photo Library (page 2)". US Drug Enforcement Administration. Archived from the original on June 23, 2008. Retrieved June 27, 2008. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)

[143] Maclean, J.R.; Macdonald, D.C.; Ogden, F.; Wilby, E., "LSD-25 and mescaline as therapeutic adjuvants." In: Abramson, H., Ed., The Use of LSD in Psychotherapy and Alcoholism, Bobbs-Merrill: New York, 1967, pp. 407–426; Ditman, K.S.; Bailey, J.J., "Evaluating LSD as a psychotherapeutic agent," pp.74–80; Hoffer, A., "A program for the treatment of alcoholism: LSD, malvaria, and nicotinic acid," pp. 353–402.

[144] LSD: The Drug

[145] Schou, Nicholas (2010). Orange Sunshine: The Brotherhood of Eternal Love and Its Quest to Spread Peace, Love, and Acid to the World. Thomas Dunne Books.

[microgram_october_2005-146] United States Drug Enforcement Administration (October 2005). "LSD BLOTTER ACID MIMIC CONTAINING 4-BROMO-2, 5-DIMETHOXY-AMPHETAMINE (DOB) SEIZED NEAR BURNS, OREGON" (PDF). Microgram Bulletin. 38 (10). Retrieved August 20, 2009.

[microgram_november_2006-147] United States Drug Enforcement Administration (November 2006). ""PURPLE" (COUGH SYRUP CONTAINING CODEINE AND OXYCODONE) IN WILKINSBURG, PENNSYLVANIA" (PDF). Microgram Bulletin. 39 (11). Retrieved August 20, 2009.

[microgram_march_2008-148] United States Drug Enforcement Administration (March 2008). "UNUSUAL "RICE KRISPIE TREAT"-LIKE BALLS CONTAINING PSILOCYBE MUSHROOM PARTS IN WARREN COUNTY, MISSOURI" (PDF). Microgram Bulletin. 41 (3). Retrieved August 20, 2009.

[ACMD_Report-149] Iversen, Les (May 29, 2013). "Temporary Class Drug Order Report on 5-6APB and NBOMe compounds" (PDF). Advisory Council on the Misuse of Drugs. Gov.Uk. p. 14. Retrieved June 16, 2013.

[microgram_march_2009-150] United States Drug Enforcement Administration (March 2009). ""SPICE" – PLANT MATERIAL(S) LACED WITH SYNTHETIC CANNABINOIDS OR CANNABINOID MIMICKING COMPOUNDS" (PDF). Microgram Bulletin. 42 (3). Retrieved August 20, 2009.

[microgram_november_2005-151] United States Drug Enforcement Administration (November 2005). "BULK MARIJUANA IN HAZARDOUS PACKAGING IN CHICAGO, ILLINOIS" (PDF). Microgram Bulletin. 38 (11). Retrieved August 20, 2009.

[microgram_december_2007-152] United States Drug Enforcement Administration (December 2007). "SMALL HEROIN DISKS NEAR GREENSBORO, GEORGIA" (PDF). Microgram Bulletin. 40 (12). Retrieved August 20, 2009.

[Erowid25I-NBOMe-153] Erowid. "25I-NBOMe (2C-I-NBOMe) Fatalities / Deaths". Drug Website. Erowid. Retrieved February 28, 2016.

[NY_Daily_news-154] Hastings, Deborah (May 6, 2013). "New drug N-bomb hits the street, terrifying parents, troubling cops". New York Daily News. Retrieved May 7, 2013.

[Ireland_injuries-155] Feehan, Conor (January 21, 2016). "Powerful N-Bomb drug - responsible for spate of deaths internationally - responsible for hospitalisation of six in Cork". Irish Independent. Retrieved January 22, 2016.

[ACMD_Report2-156] Iversen, Les (May 29, 2013). "Temporary Class Drug Order Report on 5-6APB and NBOMe compounds" (PDF). Advisory Council on the Misuse of Drugs. Gov.Uk. Retrieved June 16, 2013.

[157] "The Albert Hofmann Foundation". Hofmann Foundation. Retrieved September 27, 2007.

[new_research-158] "LSD & Psilocybin-Assisted Therapy for Anxiety". Retrieved October 16, 2013.

[159] DEA Public Affairs (November 16, 2001). "DEA – Publications – LSD in the US – The Drug". Web.petabox.bibalex.org. Archived from the original on April 27, 1999. Retrieved November 27, 2010. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)

[:0-160] Bogenschutz MP (2013). "Studying the effects of classic hallucinogens in the treatment of alcoholism: Rationale, methodology, and current research with psilocybin". Current Drug Abuse Reviews. 6 (1): 17–29. doi:10.2174/15733998113099990002. PMID 23627783.

[autogenerated295-161] Passie T, Halpern JH, Stichtenoth DO, Emrich HM, Hintzen A (2008). "The pharmacology of lysergic acid diethylamide: A review". CNS Neuroscience & Therapeutics. 14 (4): 295–314. doi:10.1111/j.1755-5949.2008.00059.x. PMID 19040555.

[162] Cohen, S. (1959). The therapeutic potential of LSD-25. A Pharmacologic Approach to the Study of the Mind, p251–258.

[163] "Use of d-lysergic acid diethylamide in the treatment of alcoholism". Retrieved June 20, 2012.

[164] "Use of d-Lysergic Acid Diethylamide in the Treatment of Alcoholism". Hofmann.org. November 14, 2003. Retrieved February 22, 2012.

[165] Chwelos N, Blewett DB, Smith CM, Hoffer A (1959). "Use of d-lysergic acid diethylamide in the treatment of alcoholism". Quart. J. Stud. Alcohol. 20: 577–90. PMID 13810249.

[166] Vollenweider, F. X.; Kometer, M (2010). "The neurobiology of psychedelic drugs: Implications for the treatment of mood disorders". Nature Reviews Neuroscience. 11 (9): 642–51. doi:10.1038/nrn2884. PMID 20717121.

[167] Baumeister, D; Barnes, G; Giaroli, G; Tracy, D (2014). "Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles". Therapeutic Advances in Psychopharmacology. 4 (4): 156–69. doi:10.1177/2045125314527985. PMC 4104707. PMID 25083275.

[168] "LSD-Assisted Psychotherapy". MAPS. Retrieved October 3, 2016.

[PMID18562421-169] Sessa B (2008). "Is it time to revisit the role of psychedelic drugs in enhancing human creativity?". J Psychopharmacol. 22 (8): 821–7. doi:10.1177/0269881108091597. PMID 18562421.

[PMID2723891-170] Janiger O, Dobkin de Rios M (1989). "LSD and creativity". J Psychoactive Drugs. 21 (1): 129–34. doi:10.1080/02791072.1989.10472150. PMID 2723891.

[Stafford-Golightly-171] Stafford, Peter G.; B. H. Golightly (1967). LSD, the problem-solving psychedelic. ASIN B0006BPSA0.

[PMID6054248-172] McGlothlin W, Cohen S, McGlothlin MS (1967). "Long lasting effects of LSD on normals" (PDF). Archives of General Psychiatry. 17 (5): 521–532. doi:10.1001/archpsyc.1967.01730290009002. PMID 6054248. Archived from the original (PDF) on April 30, 2011. {{cite journal}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)

[173] "Psychiater Gasser bricht sein Schweigen". July 28, 2009.

[174] LSD-Assisted Psychotherapy http://www.maps.org/research/psilo-lsd

[175] Krebs, T. S.; Johansen, P.-O. (2012). "Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials". Journal of Psychopharmacology. 26 (7): 994–1002. doi:10.1177/0269881112439253. PMID 22406913.

[176] Berlin pilot cluster headaches treatment with LSD study. LSD Alleviates 'Suicide Headaches' Archived January 10, 2012, at the Wayback Machine.

[177] "Famous LSD users". The Good Drugs Guide. Retrieved October 20, 2008.

[178] "People on psychedelics". Retrieved November 1, 2012.

[179] Feynman, Richard P. (1985). Ralph Leighton (ed.). Surely You're Joking, Mr. Feynman!: Adventures of a Curious Character. W. W. Norton. ISBN 0-393-01921-7. OCLC 10925248.

[180] Gleick, James (1992). Genius: The Life and Science of Richard Feynman. Pantheon Books. ISBN 0-679-40836-3. OCLC 243743850.

[181] Alderson, Jeremy (April 20, 2010). "Q&A with Jerry Garcia: Portrait of an Artist as a Tripper". Relix Magazine. Archived from the original on May 21, 2010. Retrieved June 29, 2013. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)

[182] "The Bill Gates Interview". Playboy. July 1994.

[OpenCulture-183] Colman, Dan (October 2011). "Aldous Huxley's LSD Death Trip". Retrieved November 1, 2011.

[184] Bosker, Bianca (October 21, 2011). "The Steve Jobs Reading List: The Books And Artists That Made The Man". The Huffington Post. Retrieved October 23, 2011.

[FOOTNOTESheff2000182-185] Sheff 2000, p. 182.

[186] "Lucy in the Sky with Diamonds LSD". snopes.com. Retrieved June 20, 2012.

[weeklystandard-187] Matus, Victorino (June 2004). "The Truth Behind "LSD"". The Weekly Standard.

[188] Ann Harrison (January 16, 2006). "LSD: The Geek's Wonder Drug?". Wired. Wired. Retrieved March 11, 2008. Like Herbert, many scientists and engineers also report heightened states of creativity while using LSD. During a press conference on Friday, Hofmann revealed that he was told by Nobel-prize-winning chemist Kary Mullis that LSD had helped him develop the polymerase chain reaction that helps amplify specific DNA sequences.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]

[14]

[15]

[16]

[17]

[18]

[19]

[20]

[21]

[22]

[23]

[24]

[25]

[26]

[27]

[28]

[29]

[30]

[31]

[32]

[33]

[34]

[35]

[36]

[37]

[38]

[39]

[40]

[41]

[42]

[43]

[44]

[45]

[46]

[47]

[48]

[49]

[50]

[51]

[52]

[53]

[54]

[55]

[56]

[57]

[58]

[59]

[60]

[61]

[62]

[63]

[64]

[65]

[66]

[67]

[68]

[69]

[70]

[71]

[72]

[73]

[74]

[75]

[76]

[77]

[78]

[79]

[80]

[81]

[82]

[83]

[84]

[85]

[86]

[87]

[88]

[89]

[90]

[91]

[92]

[93]

[94]

[95]

[96]

[97]

[98]

[99]

[100]

@@ Line 167: / Line 167: @@
 Most [[serotonergic psychedelic]]s are not significantly [[dopaminergic]], and LSD is therefore atypical in this regard. The agonism of the [[dopamine receptor D2|D<sub>2</sub> receptor]] by LSD may contribute to its psychoactive effects in humans.<ref name="nichols_closes_shop">{{cite journal |vauthors=Marona-Lewicka D, Thisted RA, Nichols DE | title = Distinct temporal phases in the behavioral pharmacology of LSD: Dopamine D2 receptor-mediated effects in the rat and implications for psychosis | journal = Psychopharmacology | volume = 180 | issue = 3 | pages = 427–435 | year = 2005 | pmid = 15723230 | pmc =  | doi = 10.1007/s00213-005-2183-9 }}</ref><ref>{{cite web|last=Nichols|first=David|title=The End of a Chemistry Era... Dave Nichols Closes Shop|url=https://www.erowid.org/culture/characters/nichols_david/nichols_david_interview1.shtml|accessdate=September 24, 2013|date=November 2012}}</ref>
-LSD binds to most serotonin receptor subtypes except for the [[5-HT3 receptor|5-HT<sub>3</sub>]] and [[5-HT4 receptor|5-HT<sub>4</sub> receptor]]s. However, most of these receptors are affected at too low affinity to be sufficiently activated by the brain concentration of approximately 10–20&nbsp;[[Molar concentration|nM]].<ref name="nichols">{{cite journal | author = Nichols DE | title = Hallucinogens | journal = Pharmacology & Therapeutics | volume = 101 | issue = 2 | pages = 131–81 | year = 2004 | pmid = 14761703 | doi = 10.1016/j.pharmthera.2003.11.002 | url = http://www.erowid.org/references/refs_view.php?A=ShowDoc1&ID=6318 }}</ref> In humans, recreational doses of LSD can affect [[5-HT1A receptor|5-HT<sub>1A</sub>]] (K<sub>i</sub>=1.1nM), [[5-HT2A receptor|5-HT<sub>2A</sub>]] (K<sub>i</sub>=2.9nM), [[5-HT2B receptor|5-HT<sub>2B</sub>]] (K<sub>i</sub>=4.9nM), [[5-HT2C receptor|5-HT<sub>2C</sub>]] (K<sub>i</sub>=23nM), [[5-HT5A receptor|5-HT<sub>5A</sub>]] (K<sub>i</sub>=9nM [in cloned rat tissues]), and [[5-HT6 receptor|5-HT<sub>6</sub> receptors]] (K<sub>i</sub>=2.3nM).<ref name="Aghajanian" /><ref>{{cite web|url=http://pdsp.cwru.edu/pdsp.php |accessdate=June 28, 2013 |title=PDSP database |deadurl=yes |archiveurl=https://web.archive.org/web/20130517014015/http://pdsp.cwru.edu/pdsp.php |archivedate=May 17, 2013 }}</ref>  [[5-HT5B receptor|5-HT<sub>5B</sub> receptors]], which are not present in humans, also have a high affinity for LSD.<ref>{{cite journal | author = Nelson DL | title = 5-HT5 receptors | journal = Current drug targets. CNS and neurological disorders | volume = 3 | issue = 1 | pages = 53–8 | date = February 2004 | pmid = 14965244 | doi = 10.2174/1568007043482606 }}</ref>  The psychedelic effects of LSD are attributed to [[Crosstalk (biology)|cross-activation]] of 5-HT<sub>2A</sub> [[GPCR oligomer|receptor heteromers]].<ref>{{cite journal  |vauthors=Moreno JL, etal | year = 2011 | title = Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists| url = | journal = Neurosci Lett. | volume =  493| issue = 3| pages = 76–79| doi = 10.1016/j.neulet.2011.01.046 | pmid = 21276828 | pmc=3064746}}</ref> Many but not all 5-HT<sub>2A</sub> [[agonist]]s are psychedelics and 5-HT<sub>2A</sub> [[Receptor antagonist|antagonists]] block the psychedelic activity of LSD. LSD exhibits [[functional selectivity]] at the 5-HT<sub>2A</sub> and 5HT<sub>2C</sub> receptors in that it activates the  [[signal transduction]] enzyme [[phospholipase A2]] instead of activating the enzyme [[phospholipase C]] as the endogenous ligand serotonin does.<ref>{{cite journal |vauthors=Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, Miller KJ, Spedding M, Mailman RB | title = Functional Selectivity and Classical Concepts of Quantitative Pharmacology | volume = 320 | issue = 1 | pages = 1–13 | date = June 27, 2006 | pmid = 16803859 | doi = 10.1124/jpet.106.104463 | periodical = JPET }}</ref> Exactly how LSD produces its effects is unknown, but it is thought that it works by increasing [[Glutamate (neurotransmitter)|glutamate]] release in the [[cerebral cortex]]<ref name="nichols" /> and therefore [[EPSP|excitation]] in this area, specifically in layers IV and V.<ref>BilZ0r. "[http://www.erowid.org/psychoactives/pharmacology/pharmacology_article2.shtml The Neuropharmacology of Hallucinogens: a technical overview]". [[Erowid]], v3.1 (August 2005).</ref> LSD, like many other drugs of abuse, has been shown to activate [[DARPP-32]]-related pathways.<ref>{{cite journal |vauthors=Svenningsson P, Nairn AC, Greengard P | title = DARPP-32 mediates the actions of multiple drugs of abuse | journal = AAPS Journal | volume = 7 | issue = 2 | pages = E353–E360 | year = 2005 | pmid = 16353915 | pmc = 2750972 | doi = 10.1208/aapsj070235 | url = http://www.aapsj.org/view.asp?art=aapsj070235 }}</ref> The drug enhances dopamine D<sub>2</sub> receptor [[GPCR oligomer|protomer]] recognition and [[cell signaling|signaling]] of D<sub>2</sub>–5-HT<sub>2A</sub> receptor complexes,<ref name="pmid24309097">{{cite journal  |vauthors=Borroto-Escuela DO, etal | year = 2014 | title = Hallucinogenic 5-HT2AR agonists LSD and DOI enhance dopamine D2R protomer recognition and signaling of D2-5-HT2A heteroreceptor complexes.| url = | journal = Biochem Biophys Res Commun | volume =  443| issue = 1| pages = 278–84| doi = 10.1016/j.bbrc.2013.11.104 | pmid = 24309097 }}</ref> which may contribute to its psychotic effects.<ref name="pmid24309097" />
+LSD binds to most serotonin receptor subtypes except for the [[5-HT3 receptor|5-HT<sub>3</sub>]] and [[5-HT4 receptor|5-HT<sub>4</sub> receptor]]s. However, most of these receptors are affected at too low affinity to be sufficiently activated by the brain concentration of approximately 10–20&nbsp;[[Molar concentration|nM]].<ref name="nichols">{{cite journal | author = Nichols DE | title = Hallucinogens | journal = Pharmacology & Therapeutics | volume = 101 | issue = 2 | pages = 131–81 | year = 2004 | pmid = 14761703 | doi = 10.1016/j.pharmthera.2003.11.002 | url = http://www.erowid.org/references/refs_view.php?A=ShowDoc1&ID=6318 }}</ref> In humans, recreational doses of LSD can affect [[5-HT1A receptor|5-HT<sub>1A</sub>]] (K<sub>i</sub>=1.1nM), [[5-HT2A receptor|5-HT<sub>2A</sub>]] (K<sub>i</sub>=2.9nM), [[5-HT2B receptor|5-HT<sub>2B</sub>]] (K<sub>i</sub>=4.9nM), [[5-HT2C receptor|5-HT<sub>2C</sub>]] (K<sub>i</sub>=23nM), [[5-HT5A receptor|5-HT<sub>5A</sub>]] (K<sub>i</sub>=9nM [in cloned rat tissues]), and [[5-HT6 receptor|5-HT<sub>6</sub> receptors]] (K<sub>i</sub>=2.3nM).<ref name="Aghajanian" /><ref>{{cite web|url=http://pdsp.cwru.edu/pdsp.php |accessdate=June 28, 2013 |title=PDSP database |deadurl=yes |archiveurl=https://web.archive.org/web/20130517014015/http://pdsp.cwru.edu/pdsp.php |archivedate=May 17, 2013 }}</ref>  [[5-HT5B receptor|5-HT<sub>5B</sub> receptors]], which are not present in humans, also have a high affinity for LSD.<ref>{{cite journal | author = Nelson DL | title = 5-HT5 receptors | journal = Current drug targets. CNS and neurological disorders | volume = 3 | issue = 1 | pages = 53–8 | date = February 2004 | pmid = 14965244 | doi = 10.2174/1568007043482606 }}</ref>  The psychedelic effects of LSD are attributed to [[Crosstalk (biology)|cross-activation]] of 5-HT<sub>2A</sub> [[GPCR oligomer|receptor heteromers]].<ref>{{cite journal  |vauthors=Moreno JL, etal | year = 2011 | title = Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists| url = | journal = Neurosci Lett. | volume =  493| issue = 3| pages = 76–79| doi = 10.1016/j.neulet.2011.01.046 | pmid = 21276828 | pmc=3064746}}</ref> Many but not all 5-HT<sub>2A</sub> [[agonist]]s are psychedelics and 5-HT<sub>2A</sub> [[Receptor antagonist|antagonists]] block the psychedelic activity of LSD. LSD exhibits [[functional selectivity]] at the 5-HT<sub>2A</sub> and 5HT<sub>2C</sub> receptors in that it activates the  [[signal transduction]] enzyme [[phospholipase A2]] instead of activating the enzyme [[phospholipase C]] as the endogenous ligand serotonin does.<ref>{{cite journal |vauthors=Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, Miller KJ, Spedding M, Mailman RB | title = Functional Selectivity and Classical Concepts of Quantitative Pharmacology | volume = 320 | issue = 1 | pages = 1–13 | date = June 27, 2006 | pmid = 16803859 | doi = 10.1124/jpet.106.104463 | periodical = JPET }}</ref> Exactly how LSD produces its effects is unknown, but it is thought that it works by increasing [[Glutamate (neurotransmitter)|glutamate]] release in the [[cerebral cortex]]<ref name="nichols" /> and therefore [[EPSP|excitation]] in this area, specifically in layers IV and V.<ref>BilZ0r. "[http://www.erowid.org/psychoactives/pharmacology/pharmacology_article2.shtml The Neuropharmacology of Hallucinogens: a technical overview]". [[Erowid]], v3.1 (August 2005).</ref> LSD, like many other drugs of recreational use, has been shown to activate [[DARPP-32]]-related pathways.<ref>{{cite journal |vauthors=Svenningsson P, Nairn AC, Greengard P | title = DARPP-32 mediates the actions of multiple drugs of abuse | journal = AAPS Journal | volume = 7 | issue = 2 | pages = E353–E360 | year = 2005 | pmid = 16353915 | pmc = 2750972 | doi = 10.1208/aapsj070235 | url = http://www.aapsj.org/view.asp?art=aapsj070235 }}</ref> The drug enhances dopamine D<sub>2</sub> receptor [[GPCR oligomer|protomer]] recognition and [[cell signaling|signaling]] of D<sub>2</sub>–5-HT<sub>2A</sub> receptor complexes,<ref name="pmid24309097">{{cite journal  |vauthors=Borroto-Escuela DO, etal | year = 2014 | title = Hallucinogenic 5-HT2AR agonists LSD and DOI enhance dopamine D2R protomer recognition and signaling of D2-5-HT2A heteroreceptor complexes.| url = | journal = Biochem Biophys Res Commun | volume =  443| issue = 1| pages = 278–84| doi = 10.1016/j.bbrc.2013.11.104 | pmid = 24309097 }}</ref> which may contribute to its psychotic effects.<ref name="pmid24309097" />
 The [[crystal structure]] of LSD bound in its active state to a [[serotonin receptor]], specifically the 5-HT<sub>2B</sub> receptor, has recently (2017) been elucidated for the first time.<ref name="Phys.org2017">{{cite web |url= |title=This is LSD Attached to a Brain Cell Serotonin Receptor (Update) |author=[[UNC Health Care]] |date=26 January 2017 |website=[[Phys.org]] |publisher=[[Phys.org]] |access-date=}}</ref><ref name="ScienceDaily2017b">{{cite web |url= |title=Structure of LSD and its receptor explains its potency |author=[[Cell Press]] |date=26 January 2017 |website=[[Science Daily]] |publisher=[[Science Daily]] |access-date=}}</ref><ref name="WackerWang2017">{{cite journal|last1=Wacker|first1=Daniel|last2=Wang|first2=Sheng|last3=McCorvy|first3=John D.|last4=Betz|first4=Robin M.|last5=Venkatakrishnan|first5=A.J.|last6=Levit|first6=Anat|last7=Lansu|first7=Katherine|last8=Schools|first8=Zachary L.|last9=Che|first9=Tao|last10=Nichols|first10=David E.|last11=Shoichet|first11=Brian K.|last12=Dror|first12=Ron O.|last13=Roth|first13=Bryan L.|title=Crystal Structure of an LSD-Bound Human Serotonin Receptor|journal=Cell|volume=168|issue=3|year=2017|pages=377–389.e12|issn=0092-8674|doi=10.1016/j.cell.2016.12.033}}</ref> The LSD-bound 5-HT<sub>2B</sub> receptor is regarded as an excellent model system for the 5-HT<sub>2A</sub> receptor and the structure of the LSD-bound 5-HT<sub>2B</sub> receptor was used in the study as a template to determine the structural features necessary for the activity of LSD at the 5-HT<sub>2A</sub> receptor.<ref name="Phys.org2017" /><ref name="ScienceDaily2017b" /><ref name="WackerWang2017" /> The diethylamide moiety of LSD was found to be a key component for its activity, which is in accordance with the fact that the related [[lysergamide]] [[lysergic acid amide]] (LSA) is far less hallucinogenic in comparison.<ref name="WackerWang2017" /> LSD was found to stay bound to both the 5-HT<sub>2A</sub> and 5-HT<sub>2B</sub> receptors for an exceptionally long amount of time, which may be responsible for its long [[duration of action]] in spite of its relatively short terminal half-life.<ref name="Phys.org2017" /><ref name="ScienceDaily2017b" /><ref name="WackerWang2017" /> The extracellular loop 2 leucine 209 residue of the 5-HT2B receptor forms a 'lid' over LSD that appears to trap it in the receptor, and this was implicated in the [[potency (pharmacology)|potency]] and [[functional selectivity]] of LSD and its very slow [[dissociation rate]] from the 5-HT<sub>2</sub> receptors.<ref name="Phys.org2017" /><ref name="ScienceDaily2017b" /><ref name="WackerWang2017" />

v t e Ergolines
Lysergic acid derivatives	2-Bromo-LSD (BOL-148) Amesergide Bromerguride (2-bromolisuride) Bromocriptine Cabergoline Dihydroergocornine Dihydroergocristine Dihydroergocryptine Dihydroergometrine (Dihydroergonovine, Dihydroergobasine) Dihydroergosine Dihydroergotamine Epicriptine Ergine (LSA; LA-111; Lysergamide) Ergocornine Ergocristine Ergocryptine Ergoloid (Dihydroergotoxine) Ergometrine (Ergonovine, Ergobasine) Ergometrinine Ergostine Ergotamine Ergotoxine Ergovaline Fludihydroergotamine Lisuride LY-215,840 LSH Lysergic acid Lysergic acid methyl ester Lysergine Lysergol Mergocriptine Mesulergine Metergoline Metergotamine MIPLA Methysergide Propisergide Sergolexole
Psychedelic lysergamides	1B-LSD 1cP-LSD 1P-ETH-LAD 1P-LSD AL-LAD ALD-52 BU-LAD CYP-LAD Diallyllysergamide (DAL) Dimethyllysergamide (DAM-57) ECPLA Ergonovine ETFELA ETH-LAD IP-LAD LAMPA LAE-32 LSD (lysergide) LPD-824 LSM-775 LSH LSD-Pip Lysergic Acid 2-Butylamide Lysergic Acid 2,4-Dimethylazetidide Lysergic Acid 3-Pentylamide Lysergic acid cyclobutylamide Lysergic acid cyclopentylamide Methylergometrine (Methylergonovine, Methylergobasine) MIPLA MLD-41 PARGY-LAD PRO-LAD
Clavines	9-Deacetoxyfumigaclavine C Agroclavine Chanoclavine Chanoclavine II Costaclavin Cycloclavine Elymoclavine Epoxyagroclavine Festuclavine Fumigaclavine A Fumigaclavine B Fumigaclavine C Paliclavine Penniclavine Setoclavine
Other ergolines	Acetergamine Brazergoline Cianergoline CY-208,243 Delergotrile Disulergine Dosergoside Ergoline Etisulergine Lergotrile Nicergoline Pergolide Proterguride Romergoline Terguride Tiomergine Voxergolide
Related compounds	Adrogolide Naxagolide Quinagolide
Natural sources	Achnatherum robustum (Sleepy Grass) Claviceps spp. (Ergot) Morning glory: Argyreia nervosa (Hawaiian Baby Woodrose), Ipomoea spp.(Morning Glory, Tlitliltzin, Badoh Negro), Rivea corymbosa (Coaxihuitl, Ololiúqui)